Conditions: Chronic Hepatitis B
Keywords: Hepatitis B Virus Chronic Hepatitis B HBV Hepatitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 82
Healthy volunteers: yes

Brief summary:
This is a phase 1/2 study in which healthy adult subjects and subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 or placebo and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity (only in subjects with chronic HBV).

In the single ascending dose (SAD) part, Part A, healthy adult subjects will receive one dose of VIR-2218 or placebo, administered subcutaneously (SC). In the multiple ascending dose (MAD) parts, Part B \& Part C, subjects with chronic HBV infection will receive two doses of VIR-2218 or placebo every 4 weeks administered SC.

Detailed description:

Arms:
arm 1: Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC arm 2: Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC arm 3: Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC arm 4: Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC arm 5: Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC arm 6: Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC arm 7: Healthy subjects received a single dose of placebo administered SC arm 8: Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart. arm 9: Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart. arm 10: Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart. arm 11: Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart. arm 12: Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart. arm 13: Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart. arm 14: Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart. arm 15: Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.

Interventions: intervention 1: VIR-2218 intervention 2: Placebo
Intervention descriptions: intervention 1: VIR-2218 given by subcutaneous injection intervention 2: Sterile normal saline (0.9% NaCl) given by subcutaneous injection

Protocol document:
Prot_000.pdf: 
Official Title: A Phase 1/2, Randomized, Placebo-Controlled 
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, 
and Antiviral Activity of VIR-2218 
 
 
NCT Number: NCT03672188 
 
 
Document Date: Amendment 2, 27 March 2019 


CLINICAL STUDY PROTOCOL 
Study Title: 
A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate 
the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity 
of VIR-2218 
Sponsor: 
Vir Biotechnology, Inc. 
499 Illinois Street, Suite 500 
San Francisco, CA 94158, USA 
Investigational 
Product: 
VIR-2218 
Clinicaltrials.gov ID: 
To be determined 
Indication: 
Chronic Hepatitis B (HBV) Infection 
Protocol ID: 
VIR-2218-1001 
Vir Study Director 
& Medical Monitor: 
Protocol 
Version/Date: 
Amendment 2: 
27 March 2019 
CONFIDENTIALITY STATEMENT 
This document contains confidential information that is the property of Vir Biotechnology Inc. 
This confidential information is being provided for the purpose of evaluating or conducting a 
clinical study. This confidential information will be protected by you and your staff against 
disclosure to or use by third parties, except as necessary for the evaluation or conduct of the 
study. 
PPD


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 2 
27 MAR 2019 
TABLE OF CONTENTS 
TABLE OF CONTENTS .................................................................................................................2 
LIST OF IN-TEXT TABLES ..........................................................................................................6 
LIST OF IN-TEXT FIGURES.........................................................................................................6 
PROTOCOL SYNOPSIS.................................................................................................................7 
1.
INTRODUCTION ......................................................................................................17 
1.1. Background ......................................................................................................................17 
1.2. VIR-2218 .........................................................................................................................19 
1.2.1. 
VIR-2218 Description .......................................................................................19 
1.2.2. 
Rationale for VIR-2218 for the Treatment of HBV Infection ..........................19 
1.2.3. 
Nonclinical Data ...............................................................................................19 
1.2.4. 
Rationale for Dose Selection .............................................................................19 
1.3. Overall Risk/Benefit Assessment ....................................................................................22 
2.
OBJECTIVES .............................................................................................................23 
2.1. Part A Objectives .............................................................................................................23 
2.2. Part B/C Objectives .........................................................................................................23 
3.
ENDPOINTS ..............................................................................................................24 
3.1. Part A Endpoints ..............................................................................................................24 
3.2. Part B/C Endpoints ..........................................................................................................24 
4.
STUDY DESIGN .......................................................................................................26 
4.1. Treatment Plan and Regimen ..........................................................................................26 
4.1.1. 
Part A Single Ascending Dose Phase in Healthy Adult Subjects .....................26 
4.1.2. 
Part B/C Multiple Ascending Dose Phase in Non-Cirrhotic Adult 
Subjects with Chronic HBV Infection on Nucleoside/Nucleotide 
Therapy .............................................................................................................27 
4.2. Discontinuations ..............................................................................................................28 
4.3. Replacement of Subjects .................................................................................................28 
4.4. Safety Review Committee ...............................................................................................28 
4.5. Study Drug Dosing, Study Progression, and Dose Escalation ........................................29 
4.5.1. 
Part A Study Drug Dosing, Study Progression, and Dose Escalation in 
Planned Cohorts ................................................................................................29 
4.5.2. 
Part A Optional Cohorts and Floater Subjects ..................................................29 


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 3 
27 MAR 2019 
4.5.3. 
Part B Study Drug Dosing, Study Progression, and Dose Escalation in 
Planned Cohorts ................................................................................................29 
4.5.4. 
Part C Study Drug Dosing, Study Progression, and Dose Escalation in 
Planned Cohorts ................................................................................................30 
4.5.5. 
Part B/C Optional Cohorts and Floater Subjects...............................................30 
4.6. Stopping Rules .................................................................................................................31 
4.6.1. 
Cohort Stopping Rules ......................................................................................31 
4.6.2. 
Individual Subject Stopping Rules in Part B/C .................................................31 
5. 
SUBJECT POPULATION .........................................................................................32 
5.1. Number of Subjects and Subject Selection .....................................................................32 
5.2. Part A Inclusion Criteria ..................................................................................................32 
5.3. Part A Exclusion Criteria .................................................................................................33 
5.4. Part B/C Inclusion Criteria ..............................................................................................34 
5.5. Part B/C Exclusion Criteria .............................................................................................35 
6. 
INVESTIGATIONAL MEDICINAL PRODUCTS ....................................................37 
6.1. Randomization, Blinding, and Treatment Codes ............................................................37 
6.1.1. 
Procedures for Breaking of Treatment Codes ...................................................37 
6.2. Description and Handling of VIR-2218 and Placebo ......................................................37 
6.2.1. 
Formulation .......................................................................................................37 
6.2.2. 
Packaging and Labeling ....................................................................................37 
6.2.3. 
Storage and Handling ........................................................................................37 
6.2.4. 
Dosage and Administration of VIR-2218 .........................................................38 
6.3. Investigational Product Accountability ...........................................................................39 
6.4. Concomitant Therapy ......................................................................................................39 
6.4.1. 
Permitted Concomitant Medications .................................................................39 
6.4.2. 
Prohibited Concomitant Medications ................................................................40 
6.5. NUC Therapy ..................................................................................................................40 
6.6. Contraceptive Requirements ...........................................................................................40 
7. 
STUDY PROCEDURES ............................................................................................42 
7.1. Procedures and Specifications .........................................................................................42 
7.1.1. 
Medical History .................................................................................................42 
7.1.2. 
Assessment of Antiviral Activity and Development of Resistance ..................42 
7.1.3. 
Screening Viral Serology Parameters ...............................................................42 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 4 
27 MAR 2019 
7.1.4. 
Pharmacokinetic Assessments ..........................................................................42 
7.2. Safety Assessments .........................................................................................................43 
7.2.1. 
Physical Examination ........................................................................................43 
7.2.2. 
Alcohol Assessment ..........................................................................................43 
7.2.3. 
Height and Weight ............................................................................................43 
7.2.4. 
Vital Signs .........................................................................................................43 
7.2.5. 
Electrocardiogram .............................................................................................43 
7.2.6. 
Pregnancy Testing .............................................................................................45 
7.2.7. 
Clinical Laboratory Assessments ......................................................................46 
7.2.8. 
FibroScan ..........................................................................................................48 
8.
ADVERSE EVENTS MANAGEMENT ....................................................................49 
8.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events .........49 
8.1.1. 
Adverse Events .................................................................................................49 
8.1.2. 
Serious Adverse Events.....................................................................................49 
8.1.3. 
Clinical Laboratory Abnormalities and Other Abnormal Assessments 
as Adverse Events or Serious Adverse Events ..................................................50 
8.2. Assessment of Adverse Events and Serious Adverse Events ..........................................51 
8.2.1. 
Assessment of Causality for Study Drugs and Procedures ...............................51 
8.2.2. 
Assessment of Severity .....................................................................................51 
8.3. Investigator Requirements and Instructions for Reporting Adverse Events and 
Serious Adverse Events to Vir ........................................................................................51 
8.4. Vir Reporting Requirements ............................................................................................52 
8.5. Special Situations Reports ...............................................................................................52 
8.5.1. 
Definitions of Special Situations .......................................................................52 
8.5.2. 
Instructions for Reporting Special Situations ...................................................53 
9.
STATISTICAL CONSIDERATIONS ........................................................................55 
9.1. Objectives ........................................................................................................................55 
9.2. Endpoints .........................................................................................................................55 
9.3. Analysis Conventions ......................................................................................................55 
9.3.1. 
Analysis Sets .....................................................................................................55 
9.3.2. 
Data Handling Conventions ..............................................................................55 
9.4. Demographic Data and Baseline Characteristics ............................................................56 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 5 
27 MAR 2019 
9.5. Safety Analysis ................................................................................................................56 
9.5.1. 
Adverse Events .................................................................................................56 
9.5.2. 
Laboratory Evaluations .....................................................................................56 
9.5.3. 
Other Safety Evaluations...................................................................................56 
9.6. Pharmacokinetic/Pharmacodynamic Analysis ................................................................56 
9.7. Antiviral Activity Analysis ..............................................................................................57 
9.8. Sample Size .....................................................................................................................57 
10.
RESPONSIBILITIES .................................................................................................58 
10.1. Investigator and Sponsor Responsibilities ..................................................................58 
10.1.1. Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC) Approval..................................................................................................58 
10.1.2. Informed Consent ..............................................................................................58 
10.1.3. Confidentiality ..................................................................................................58 
10.1.4. Study Files and Retention of Records ...............................................................59 
10.1.5. Electronic Case Report Forms (eCRF) .............................................................59 
10.1.6. Good Clinical Practice ......................................................................................59 
10.1.7. Drug Accountability ..........................................................................................59 
10.1.8. Quality Control and Assurance .........................................................................59 
10.1.9. Protocol Compliance .........................................................................................60 
10.1.10. Protocol Modifications ......................................................................................60 
10.1.11. Study Report and Publications ..........................................................................60 
10.2. Study Monitoring ........................................................................................................60 
10.2.1. Study Discontinuation .......................................................................................61 
11.
REFERENCES ...........................................................................................................62 
12.
APPENDICES ............................................................................................................64 
Appendix 1. 
Investigator Signature Page .............................................................................65 
Appendix 2. 
Part A Schedule of Study Assessments for SAD Cohorts in Healthy Adult 
Subjects ............................................................................................................66 
Appendix 3. 
Part B/C Schedule of Study Assessments for MAD Cohorts in Subjects 
with Chronic HBV Infection ............................................................................69 
Appendix 4. 
Part A Pharmacokinetic Assessment Timepoints ............................................73 
Appendix 5. 
Part B/C Pharmacokinetic Assessment Timepoints .........................................74 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 6 
27 MAR 2019 
Appendix 6. 
Cohort Dosing Schedule ..................................................................................75 
LIST OF IN-TEXT TABLES 
Table 2. 
Part A Dose Escalation Plan ............................................................................21 
Table 3. 
Part B/C Dose Escalation Plan .........................................................................22 
Table 4. 
Study Drug Dose and Administration ..............................................................39 
Table 5. 
T-Wave Morphology Categories (Assessed Manually) ...................................45 
Table 6. 
Clinical Laboratory Tests .................................................................................47 
LIST OF IN-TEXT FIGURES 
Figure 1. 
SAD Study Design for Part A ..........................................................................26 
Figure 2. 
MAD Study Design for Part B/C .....................................................................26 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 7 
27 MAR 2019 
PROTOCOL SYNOPSIS 
Study Title: 
A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate 
the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of 
VIR-2218 
Clinical 
Investigative Sites 
Planned: 
Part A is planned to be conducted at 1 clinical investigative site. 
Part B/C are planned to be conducted at multiple clinical 
investigative sites in the Asia-Pacific region. 
Phase 
Part A: Phase 1 Single Ascending Dose (SAD) 
Part B/C: Phase 2 Multiple Ascending Dose (MAD) 
Number of Subjects 
Planned: 
Up to 104 subjects 
Target Population: 
Part A: Up to 56 healthy adult subjects 
Part B/C: Up to 48 non-cirrhotic adult subjects with chronic 
hepatitis B virus (HBV) infection on nucleos(t)ide reverse 
transcriptase inhibitor (NUC) therapy 
Diagnosis and Main 
Eligibility Criteria 
Part A will include healthy adult subjects. Part B/C will include 
non-cirrhotic adult subjects with chronic HBV infection on 
NUC therapy.  
Duration of Study 
Participation: 
Part A: The estimated total time on study, inclusive of screening 
and follow-up, for each subject is up to 16 weeks. The duration of 
treatment is a single dose, which can consist of up to 
3 subcutaneous (SC) injections based on the assigned dose level. 
Part B/C: The estimated total time on study, inclusive of 
screening and follow-up, for each subject is up to 20 weeks. For 
subjects requiring additional HBsAg monitoring, the estimated 
total time on study is up to 52 weeks. The duration of treatment is 
2 doses 4 weeks apart, consisting of up to 2 SC injections per dose 
based on the assigned dose level. 
Duration of 
Follow-up: 
Part A: 12 weeks after study drug administration 
Part B/C: All subjects should be followed until Week 16. 
Additional HBsAg monitoring is required for subjects with HBsAg 
levels with a > 10% decrease from the Day 1 predose level at the 
Week 16 visit. Visits will occur every 4 weeks starting at Week 20 
up to Week 48 or until the HBsAg level returns to > 90% of the 
Day 1 predose level. Additional HBsAg monitoring may be 
discontinued at the Sponsor’s discretion based on emerging data.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 8 
27 MAR 2019 
Objective(s): 
Part A 
The primary objective is: 
•
To evaluate the safety and tolerability of a single dose of
VIR-2218 in healthy adult subjects
The secondary objective is: 
•
To characterize the pharmacokinetics (PK) of VIR-2218 in
healthy adult subjects
Part B/C 
The primary objective is: 
•
To evaluate the safety and tolerability of multiple doses of
VIR-2218 in non-cirrhotic subjects with HBeAg-negative
(Part B) and HBeAg-positive (Part C) chronic HBV infection
on NUC therapy
The secondary objectives are: 
•
To characterize the PK of VIR-2218 in non-cirrhotic subjects
with chronic HBV infection on NUC therapy
•
To assess the antiviral activity of VIR-2218 in non-cirrhotic
subjects with chronic HBV infection on NUC therapy
Study Design: 
This is a randomized, double-blind, placebo-controlled study of 
VIR-2218 administered subcutaneously to healthy adult 
subjects and non-cirrhotic adult subjects with chronic HBV 
infection who are on NUC therapy. The study is designed to 
evaluate the safety, tolerability, PK, and antiviral activity of 
VIR-2218. 
A Safety Review Committee (SRC) will perform ongoing 
reviews of safety and tolerability based on available study data 
collected throughout the study. 
The study will be conducted in 3 Parts: 
•
Part A: SAD phase in healthy adult subjects
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 9 
27 MAR 2019 
•
Part B: MAD phase in non-cirrhotic adult subjects with
HBeAg-negative chronic HBV infection on NUC therapy for
≥ 6 months and serum HBV DNA < 90 IU/mL
•
Part C: MAD phase in non-cirrhotic adult subjects with
HBeAg-positive chronic HBV infection on NUC therapy for
≥ 6 months and serum HBV DNA < 90 IU/mL
Four dose-level cohorts are planned for Part A: 50 mg, 100 mg, 
200 mg, and 400 mg. Two sentinel subjects will be randomized 
1:1 to VIR-2218 or placebo. These subjects will be dosed 
concurrently and monitored for 24 hours; if the investigator has 
no safety concerns, the remainder of the subjects in the same 
cohort will be dosed. The remaining subjects will be 
randomized 5:1 to VIR-2218 or placebo. Two optional cohorts 
in Part A may be added following the same stratification, 
including sentinel dosing, up to a maximum dose of 900 mg. In 
addition to the optional cohorts, a total of 8 “floater” subjects 
may be added to expand any cohort in Part A. “Floater” 
subjects are to be added in increments of 4 and randomized 3:1 
to VIR-2218 or placebo. 
Three dose-level cohorts are planned for Part B: 50 mg, 
100 mg, and 200 mg. One dose-level cohort is planned for 
Part C: 200 mg. These planned dose levels will be administered 
twice, with each subject receiving a dose on Day 1, and a 
second dose at Week 4, such that the cumulative dose received 
for these subjects will be 100 mg, 200 mg, and 400 mg (Part B) 
and 400 mg (Part C). Each cohort in Part B/C will be 
randomized 3:1 to VIR-2218 or placebo. Two optional cohorts 
in Part B and 2 optional cohorts in Part C may be added 
following the same stratification, up to a maximum dose of 
450 mg per dose (900 mg cumulative dose). In addition to the 
optional cohorts, a pool of 16 “floater” subjects may be added 
to expand any cohort in Part B and/or C if further data are 
needed. “Floater” subjects are to be added in increments of 4 
(3:1) to maintain the randomization ratio. 
All dose levels explored in Part B/C must first be completed in 
Part A with data reviewed by the SRC prior to initiating the 
dose-level cohort in subjects with chronic HBV infection.  
The cohort dosing strategy for Part B/C of this study is 
staggered; 2 dose levels in Part A (1a: 50 mg and 2a: 100 mg) 
must be completed and data must be reviewed by the SRC to 
begin dosing at the starting dose in Part B (1b: 50 mg). Part C 
will be initiated at the Part C starting dose (3c: 200 mg) at the 
same time that the equivalent Part B dose level cohort is 
initiated (3b: 200 mg). 


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 10 
27 MAR 2019 
Study Procedures: 
Part A 
Screening 
• Screening will be performed no more than 4 weeks prior to 
the Day 1 visit and will include written informed consent, 
determination of eligibility, collection of demographics and 
medical history as well as physical examination (including 
vitals), laboratory tests, 12-lead electrocardiogram (ECG) and 
other assessments per the schedule of assessments (SoA). 
Adverse events (AEs) related to screening activities must be 
collected from the time of consent onwards; any other events 
occurring during the screening period should be reported as 
medical history. All serious adverse events (SAEs) must be 
collected from the time of consent onwards. 
Inpatient Period (Day −1 to Day 2) 
• Subjects will be admitted into the clinical investigative site on 
Day −1. Eligible subjects will be randomized to receive 
VIR-2218 or placebo within 48 hours prior to study drug 
administration on Day 1. Subjects will be discharged after all 
study assessments are performed on Day 2. 
Outpatient/Follow-Up Period 
• Subjects will return to the clinical investigative site for 
in-person assessments per the SoA including but not limited 
to physical examination (including vitals), laboratory testing 
(including safety), 12-lead ECG and review of AEs and 
concomitant medication for 12 weeks after study drug 
administration. 
Part B/C 
Screening 
• Screening will be performed no more than 4 weeks prior to 
the Day 1 visit and will include written informed consent, 
determination of eligibility, collection of demographics and 
medical history as well as physical examination (including 
vitals), laboratory tests, 12-lead ECG and other assessments 
per the SoA. Adverse events related to screening activities 
must be collected from the time of consent onwards; any 
other events occurring during the screening period should be 
reported as medical history. All SAEs must be collected from 
the time of consent onwards. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 11 
27 MAR 2019 
Dosing Period (Day 1 to Week 4) 
•
The dosing period for Part B/C is outpatient. Eligible subjects
will be randomized to receive VIR-2218 or placebo within
48 hours prior to study drug administration on Day 1.
Subjects will return to the clinical investigative site at Week 4 
to receive a second dose of the same study drug administered
on Day 1.
Follow-Up Period 
•
Subjects will return to the clinical investigative site for in-
person assessments per the SoA including but not limited to
physical examination (including vitals), laboratory testing
(including safety), 12-lead ECG and review of AEs and
concomitant medication until Week 16.
Extended Follow-Up Period 
•
Subjects that require additional HBsAg monitoring will return 
to the clinical investigative site for in-person assessments per
the SoA. Visits will occur every 4 weeks starting at Week 20
for a maximum of 48 weeks from the first study drug
administration.
Investigational 
Product, Dose, and 
Mode of 
Administration: 
VIR-2218 is a synthetic, chemically modified small interfering 
RNA (siRNA) targeting HBV RNA with a covalently attached 
triantennary N-acetyl-galactosamine (GalNAc) ligand that allows 
for specific uptake by hepatocytes. VIR-2218 will be supplied as a 
sterile solution for SC injection at a free acid concentration of 
200 mg/mL. The starting dose for Parts A and B is 50 mg. The 
starting dose for Part C is 200 mg. The dose levels in Parts A, B, 
and C will not exceed the defined maximum administered dose of 
900 mg (single or cumulative). 
Reference Therapy: 
Subjects randomized to placebo will be administered sterile, 
preservative-free normal saline 0.9% solution for SC injection. 
Criteria for 
Evaluation: 
Part A 
Primary Endpoints 
•
Incidence of AEs
•
Clinical assessments including but not limited to laboratory
test results
Secondary Endpoints 
•
PK parameters of VIR-2218 and possible metabolites
(may include, but not be limited to, plasma: maximum
concentration, time to reach maximum concentration,


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 12 
27 MAR 2019 
area under the concentration versus time curve [to last 
measurable timepoint and to infinity], percent of area 
extrapolated, apparent terminal elimination half-life, 
clearance, and volume of distribution; urine: fraction 
eliminated in the urine and renal clearance) 
Part B/C 
Primary Endpoints 
•
Incidence of AEs
•
Clinical assessments including but not limited to laboratory
test results
Secondary Endpoints 
•
PK parameters of VIR-2218 and possible metabolites (may
include, but not be limited to, plasma: maximum
concentration, time to reach maximum concentration, area
under the concentration versus time curve [to last measurable
timepoint and to infinity], percent of area extrapolated,
apparent terminal elimination half-life, clearance, and volume
of distribution)
•
Maximum reduction of serum HBsAg from Day 1 until
Week 16
•
Number of subjects with serum HBsAg loss at any timepoint
•
Number of subjects with sustained serum HBsAg loss for
≥ 6 months
•
Number of subjects with anti-HBs seroconversion at any
timepoint
•
For HBeAg-positive subjects (Part C only): number of
subjects with HBeAg loss and/or anti-HBe seroconversion at
any timepoint
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 13 
27 MAR 2019 
Statistical Methods: 
Statistical analyses will be primarily descriptive. All study data 
will be presented by subject data listings. Summary tables will 
present results by cohort for each VIR-2218 dose and placebo, 
where the placebo subjects will be combined across dose cohorts. 
Descriptive statistics will be presented for continuous variables, and 
frequencies and percentages will be presented for categorical and 
ordinal variables. Percentages will be based on the number of 
non-missing values in a dose group. Details will be provided in the 
Statistical Analysis Plan. 
This study will be conducted in accordance in compliance with the protocol, International Conference 
on Harmonisation Good Clinical Practices (ICH GCP) and applicable state, local, and federal 
regulatory requirements including archiving of essential documents. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 14 
27 MAR 2019 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AE 
adverse event 
ALT 
alanine aminotransferase 
ANC 
absolute neutrophil count 
anti-HBe 
hepatitis B extracellular antibody 
anti-HBs 
hepatitis B surface antibody 
AP 
alkaline phosphatase 
AST 
aspartate aminotransferase 
AUC 
area under the curve 
BLQ 
below the limit of quantitation 
BMI 
body mass index 
BUN 
blood urea nitrogen 
cccDNA 
covalently closed circular DNA 
CLcr 
creatinine clearance 
CRF 
case report form 
CTCAE 
Common Terminology Criteria for Adverse Events 
ECG 
Electrocardiogram 
eCRF 
electronic case report form 
ET 
early term 
FDA 
Food and Drug Administration 
GalNAc 
N-acetyl-galactosamine
GCP 
Good Clinical Practice
GGT 
gamma glutamyl transferase
GLP 
Good Laboratory Practice
GNA 
glycol nucleic acid
HBcAg 
hepatitis core antigen 
HBeAg 
hepatitis B e-antigen 
HBsAg 
hepatitis surface antigen 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 15 
27 MAR 2019 
HBV 
hepatitis B virus 
HBx 
hepatitis B protein X 
HCC 
hepatocellular carcinoma 
HCV 
hepatitis C virus 
Hgb 
Hemoglobin 
HIV 
human immunodeficiency virus 
HLGT 
High-Level Group Term 
HLT 
High-Level Term 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
INR 
international normalized ratio 
IRB 
Institutional Review Board 
IWRS 
interactive web response system 
LDH 
lactate dehydrogenase 
LLN 
lower limit of normal 
LLOQ 
lower limit of quantitation 
LLT 
Lower-Level Term 
MAD 
multiple ascending dose 
MedDRA 
Medical Dictionary for Regulatory Activities 
mRNA 
messenger RNA 
NUC 
nucleos(t)ide reverse transcriptase inhibitor 
OTC 
over-the-counter 
PEG-IFN 
pegylated interferon-alpha 
PK 
Pharmacokinetics 
pgRNA 
pregenomic RNA 
PT 
Preferred Term 
Q1 
first quartile  
Q3 
third quartile  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 16 
27 MAR 2019 
RBC 
red blood cell (count) 
RT 
reverse transcriptase 
rcDNA 
relaxed-circular DNA 
SAD 
single ascending dose 
SADR 
serious adverse drug reaction 
SAE 
serious adverse event 
SC 
Subcutaneous 
SD 
standard deviation 
siRNA 
small interfering RNA 
SoA 
schedule of assessments 
SOC
System Organ Class 
SRC 
Safety Review Committee 
SUSAR 
suspected unexpected serious adverse reaction 
TAF 
tenofovir disoproxil fumarate 
TDF 
tenofovir alafenamide 
TEAE 
treatment-emergent adverse event 
US 
United States 
ULN 
upper limit of normal 
WBC 
white blood cell (count) 
WHO 
World Health Organization 
WOCBP 
women of child-bearing potential 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 17 
27 MAR 2019 
1.
INTRODUCTION
1.1. 
Background 
VIR-2218 is a synthetic small interfering RNA (siRNA) therapeutic being developed for the 
treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV infection remains an 
important global public health problem with significant morbidity and mortality (Trepo, 2014). 
According to the World Health Organization (WHO) an estimated 257 million people are living 
with chronic HBV infection worldwide (WHO, 2017; Schweitzer, 2015). Over time, chronic 
HBV infection leads to serious sequelae including cirrhosis, liver failure, hepatocellular 
carcinoma (HCC), and death. Almost 800,000 people are estimated to die annually due to 
sequelae associated with chronic HBV infection (Stanaway, 2016).  
HBV prevalence varies geographically, with a range of less than 2% in low to greater than 8% in 
high prevalence countries (Schweitzer, 2015). In high prevalence countries, such as those in sub-
Saharan Africa and East Asia, transmission occurs predominantly in infants and children by 
perinatal and horizontal routes. In more industrialized countries, new infections are highest 
among young adults and transmission occurs predominantly via injection drug use and high-risk 
sexual behaviors. The risk of developing chronic HBV infection depends on the age at the time 
of infection. While only ~10% of people infected as adults develop chronic HBV infection, 90% 
of infants infected perinatally or during the first 6 months of life, and 20–60% of children 
infected between 6 months and 5 years of age remain chronically infected. Twenty-five percent 
of people who acquire HBV during infancy and childhood will develop primary liver cancer or 
cirrhosis during adulthood. 
HBV is a DNA virus that infects, replicates, and persists in human hepatocytes (Protzer, 2012). 
The small viral genome (3.2 kb), consists of partially double-stranded, relaxed-circular DNA 
(rcDNA) and has 4 open reading frames encoding 7 proteins: HBcAg (HBV core antigen, viral 
capsid protein), HBeAg (hepatitis B e-antigen), HBV Pol/RT (polymerase, reverse transcriptase), 
PreS1/PreS2/HBsAg (large, medium, and small surface envelope glycoproteins), and HBx 
(HBV × antigen, regulator of transcription required for the initiation of infection) (Seeger, 2015; 
Tong, 2016).  
In hepatocytes, rcDNA, the form of HBV nucleic acid that is introduced by the infection virion, 
is converted into a covalently closed circular DNA (cccDNA), which persists in the host cell’s 
nucleus as an episomal chromatinized structure (Allweiss, 2017). cccDNA serves as a 
transcription template for all viral transcripts (Lucifora, 2016). Pregenomic RNA (pgRNA) 
transcripts are reverse transcribed into new rcDNA for new virions, which are secreted without 
causing cytotoxicity. In addition to infectious virions, infected hepatocytes secrete large amounts 
of genome-free subviral particles, that may exceed the number of secreted virions by 10,000-fold 
(Seeger, 2015). Random integration of the virus into the host genome can occur as well, a 
mechanism that contributes to hepatocyte transformation (Levrero, 2016). 
In acute resolving infections, the virus is cleared by effective innate and adaptive immune 
responses that include cytotoxic T cells leading to death of infected hepatocytes, and induction of 
B cells producing neutralizing antibodies that prevent the spread of the virus (Bertoletti, 2016; 
Maini, 2016; Li, 2016). In contrast, chronic infection is associated with T and B cell dysfunction, 


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 18 
27 MAR 2019 
mediated by multiple regulatory mechanisms including presentation of viral epitopes on 
hepatocytes and secretion of subviral particles (Bertoletti, 2016; Maini, 2016; Burton, 2018). 
Thus, the continued expression and secretion of viral proteins due to cccDNA persistence in 
hepatocytes is considered a key step in the inability of the host to clear the infection. 
Chronic HBV infection is a dynamic process reflecting the interaction between HBV replication 
and host immune responses. The laboratory hallmark of chronic HBV infection is persistence of 
HBsAg in the blood for greater than 6 months, and a lack of detectable anti-HBs. Chronic 
infection is divided into 4 stages based on HBV markers in blood (HBsAg, HBeAg/anti-HBe, 
HBV DNA), and liver disease based on biochemical parameters (ALT), as well as fibrosis 
markers (noninvasive or based on liver biopsy) (EASL, 2017). Overall, across the various phases 
of chronic HBV infection, only a minority of patients (less than 1% per year) clear the disease as 
measured by HBsAg seroclearance. 
Currently, there are 2 main treatment options for patients with chronic HBV infection: treatment 
with nucleos(t)ide reverse transcriptase inhibitors (NUCs) and pegylated interferon-alpha 
(PEG-IFN) (Liang, 2015). NUCs inhibit the production of infectious virions, and often reduce 
serum HBV DNA to undetectable. However, NUCs do not directly eliminate cccDNA, and 
therefore, transcription and translation of viral proteins continues. Consequently, expression of 
viral epitopes on hepatocytes, secretion of subviral particles, and immune dysfunction remain 
largely unaffected by NUC therapy. In turn, this necessitates prolonged, often lifelong therapy; 
furthermore, while NUC therapy reduces the incidence of HCC, it does not eliminate the 
increased risk of HCC that HBV infection confers. In contrast, PEG-IFN can induce long-term 
immunological control, but only in a small percentage of patients (< 10%) (Konerman, 2016). 
The high variability of response, in combination with an unfavorable safety profile make a 
significant number of patients ineligible or unwilling to undergo PEG-IFN treatment.  
The failure of NUC therapy to eradicate the virus, and the limitations of PEG-IFN therapy 
highlight the clinical need for new HBV therapies that are effective, well tolerated, and do not 
require lifelong administration. To address this unmet need, Vir is developing an investigational 
agent, VIR-2218, for the treatment of chronic HBV infection. In preclinical models, VIR-2218 
inhibits viral replication, translation, and secretion of HBsAg. Therefore, VIR-2218 has the 
potential, alone or in combination with other therapies, to achieve a functional cure of chronic 
HBV infections. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 19 
27 MAR 2019 
1.2. 
VIR2218 
1.2.1. 
VIR-2218 Description 
VIR-2218 is an siRNA targeting a region of the HBV genome that is common to all HBV viral 
transcripts. The siRNA is chemically modified using Enhanced Stabilization Chemistry Plus 
(ESC+) consisting of 2’-fluoro (2’F), 2’-O-methoxy (2’OMe) ribose sugar modifications, 
phosphorothioate backbone modifications, glycol nucleic acid (GNA) modification, and 
conjugation to a triantennary N-acetyl-galactosamine ligand (GalNAc) at the 3’ end of the sense 
strand, to facilitate delivery to hepatocytes through the asialoglycoprotein receptor (ASGPR). 
The drug product, VIR-2218, is the drug substance VIR-2218 formulated in water for 
subcutaneous (SC) injection.VIR-2218 is pharmacologically active against HBV genotypes 
A through J; see the Investigator’s Brochure for additional information on VIR-2218. 
1.2.2. 
Rationale for VIR-2218 for the Treatment of HBV Infection 
The use of siRNA offers a novel strategy for the treatment of chronic HBV infection. siRNAs are 
19-21 base-pair RNA duplexes that exploit the endogenous RNA-interference pathway to enable
sequence-specific RNA cleavage and degradation. One siRNA can have multiple antiviral
effects, including degradation of the pgRNA, thus inhibiting viral replication, and degradation of
all viral messenger RNA (mRNA) transcripts, thereby preventing expression of viral proteins.
This may result in the return of a functional immune response directed against HBV, either alone
or in combination with other therapies.
By contrast, NUCs act at a distinct part of the viral life cycle and have a different mechanism of 
action than VIR-2218. NUCs inhibit the action of HBV RNA polymerase, blocking the reverse 
transcription of the viral pgRNA to viral DNA and preventing the production of infectious 
virions. NUCs, however, do not directly impact the production of viral proteins such as HBsAg. 
Reduction of HBsAg-containing noninfectious subviral particles by VIR-2218 is considered an 
important differentiator from current treatments. 
Subjects randomized to active treatment in Part B/C of this study will receive VIR-2218 added to 
their ongoing NUC therapy. Such subjects have already been determined by their physician to 
require treatment. Based on the known mechanisms of action there is no risk for 
pharmacodynamic drug-drug interactions or overlapping toxicities between NUCs and siRNA. 
1.2.3. 
Nonclinical Data 
Refer to the Investigator’s Brochure for VIR-2218 Nonclinical data. 
1.2.4. 
Rationale for Dose Selection 
The recommended starting dose for VIR-2218 was determined by calculating the human 
equivalent doses (HEDs) of the no observed adverse effect levels (NOAELs) in the definitive 
animal toxicology studies and applying a safety margin to those HEDs. Body surface area 
(m/kg2) conversion factors were used to calculate HEDs of animal doses.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 20 
27 MAR 2019 
Although dosing in the GLP-toxicology studies was weight based, subjects will receive a fixed 
dose rather than a weight-based dose because VIR2218, like other GalNac-conjugated siRNAs, 
is taken up by the liver and minimally distributed to other organs and tissues. Therefore, 
weightbased dosing is not anticipated to reduce the inter-individual variation in the 
pharmacokinetics (PK) of VIR2218 in adults and a fixed dose has the advantage of avoiding 
potential dose calculation errors.  
The planned and optional dose levels for Part A, were determined to support Part B/C. The 
planned and optional dose levels for Part B/C are based on what is estimated to result in 
meaningful biological activity in humans, specifically the observation that other siRNAs using 
the GalNac platform have demonstrated meaningful liver target engagement at 1 to 15 mg/kg. 
Part A: Single Ascending Dose Study in Healthy Volunteers (Table 2): 
Planned dose levels: Healthy volunteers will receive a single ascending dose. Four dose-level 
cohorts are planned. Doses will be increased stepwise by a factor of 2-fold up to a maximum 
planned dose of 400 mg (Section 4.5. describes the criteria used for dose escalation). 
Optional dose level: Two optional dose levels may be added. The additional dose levels will not 
exceed 900 mg. Doses higher than 400 mg will only be administered if 400 mg is well tolerated 
in subjects based on review of all available safety data collected through Week 4.  
CCI
CCI
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 21 
27 MAR 2019 
Table 2. 
Part A Dose Escalation Plan 
Cohort 
Weight-based dose 
(mg/kg) 
Fixed dosea 
(mg) 
Dose Escalation Factor 
1a 
0.8 
50 
- 
2a 
1.7 
100 
2.0-fold 
3a 
3.3 
200 
2.0-fold 
4a 
6.7 
400 
2.0-fold 
Optional: 5a and 6a 
Up to 15 
Up to 900 
Up to 2.25-fold 
a Based on average adult weight of 60 kg 
Part B/C: Multiple Ascending Dose Study in HBeAg-negative and HBeAg-positive Subjects 
with Chronic HBV Infection (Table 3): 
Planned dose levels: HBeAg-negative subjects with chronic HBV infection will be enrolled in 
Part B and HBeAg-positive subjects with chronic HBV infection will be enrolled in Part C. 
Three dose-level cohorts for HBeAg-negative subjects are planned; dose levels will be increased 
stepwise by a factor of 2 up to a maximum planned dose level of 200 mg and a cumulative dose 
of 400 mg (Section 4.5. describes the criteria used for dose escalation). To accommodate the 
anticipated lower prevalence of HBeAg-positive patients on NUC therapy, only 1 dose level 
cohort (200 mg) is planned for HBeAg-positive subjects.  
Initiation of Part B: Part B, Cohort 1b will be initiated after cumulative review of all available 
safety data, inclusive of the Week 4 laboratory and clinical data of the last available healthy 
volunteer subject in the 100 mg cohort (Cohort 2a).   
Initiation of Part C: The only planned cohort in Part C, Cohort 3c, will initiate at the same time 
as Cohort 3b after review of all available safety data inclusive of Week 6 clinical and laboratory 
data from Cohort 2b, and according to the criteria outlined in Section 4.5. Subjects in Cohort 3c 
will receive VIR-2218 at the same dose level as subjects in Cohort 3b (200 mg administered 
twice at a dosing interval of 4 weeks). 
Optional dose levels: Two optional dose level cohorts may be added for each subject 
population. Doses higher than 200 mg will only be administered if 200 mg is well tolerated in 
subjects with chronic HBV infection based on review of all available safety data collected 
through 8 weeks after the first dose (4 weeks after the second dose). Doses can be increased 
stepwise by a factor of 1.5-fold up to a maximum optional single dose of 450 mg (cumulative 
dose of 900 mg).  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 22 
27 MAR 2019 
Table 3. 
Part B/C Dose Escalation Plan 
Cohort 
Weight-based Dose 
(mg/kg) 
Fixed Dosea (mg) 
Dose Escalation Factor 
1b 
0.8 
50 
- 
2b 
1.7 
100 
2.0-fold 
3b and 3c 
3.3 
200 
2.0-fold 
Optional: 4b and 4c 
Up to 5 
Up to 300 
Up to 1.5-fold 
Optional: 5b and 5c 
Up to 7.5 
Up to 450 
Up to 1.5-fold 
a Based on average adult weight of 60 kg 
1.3. 
Overall Risk/Benefit Assessment 
This study will provide information on the safety, PK, and antiviral activity of VIR-2218, an 
siRNA therapeutic targeting HBV, which has the potential to functionally cure chronic HBV 
infection alone or in combination with other treatment modalities. 
The potential benefits of VIR-2218 over the current standard of care for the treatment of chronic 
HBV infection are: 
•
A pangenotypic therapy for HBV infection that is well-tolerated and administered via
SC injection for a finite duration of time
•
A reduction in serum HBsAg, which may break immune tolerance against HBV and
lead to a functional cure
The safety profile of VIR-2218 has not yet been established. 
u
To further mitigate
risk, a “sentinel” dose design will be used in Part A as follows.
•
Two subjects will be randomized 1:1 to VIR-2218 or placebo and dosed concurrently
•
These subjects will be monitored for 24 hours and if the investigator has no safety
concerns, the other subjects in the same cohort are dosed. The remaining 6 subjects will
be randomized 5:1 to VIR-2218 or placebo.
During the conduct of the study, the Sponsor will perform ongoing safety reviews and the SRC 
will meet to review safety data. 
In summary, there is no approved therapy that reduces serum HBsAg in a significant percentage 
of patients. If serum HBsAg can be effectively reduced with a pangenotypic regimen, the 
anticipated safety profile would offer a favorable risk-benefit determinant in patients with 
chronic HBV infection. 
CCI
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 23 
27 MAR 2019 
2.
OBJECTIVES
2.1. 
Part A Objectives 
The primary objective is: 
•
To evaluate the safety and tolerability of a single dose of VIR-2218 in healthy adult
subjects
The secondary objective is: 
•
To characterize the PK of VIR-2218 in healthy adult subjects
2.2. 
Part B/C Objectives 
The primary objective is: 
•
To evaluate the safety and tolerability of multiple doses of VIR-2218 in non-cirrhotic
subjects with HBeAg-negative (Part B) and HBeAg-positive (Part C) chronic HBV
infection on NUC therapy
The secondary objectives are: 
•
To characterize the PK of VIR-2218 in non-cirrhotic subjects with chronic HBV
infection on NUC therapy
•
To assess the antiviral activity of VIR-2218 in non-cirrhotic subjects with chronic
HBV infection on NUC therapy
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 24 
27 MAR 2019 
3.
ENDPOINTS
3.1. 
Part A Endpoints 
The primary endpoints are: 
•
Incidence of AEs
•
Clinical assessments including but not limited to laboratory test results
The secondary endpoints are: 
•
PK parameters of VIR-2218 and possible metabolites (may include, but not limited to
plasma: maximum concentration, time to reach maximum concentration, area under
the concentration versus time curve [to last measurable timepoint and to infinity],
percent of area extrapolated, apparent terminal elimination half-life, clearance, and
volume of distribution; urine: fraction eliminated in the urine and renal clearance)
3.2. 
Part B/C Endpoints 
The primary endpoints are: 
•
Incidence of AEs
•
Clinical assessments including but not limited to laboratory test results
The secondary endpoints are: 
•
PK parameters of VIR-2218 and possible metabolites (may include, but not limited to
plasma: maximum concentration, time to reach maximum concentration, area under
the concentration versus time curve [to the last measurable timepoint and to infinity],
apparent terminal elimination half-life, clearance, and volume of distribution)
•
Maximum reduction of serum HBsAg from Day 1 until Week 16
•
Number of subjects with serum HBsAg loss at any timepoint
•
Number of subjects with sustained serum HBsAg loss for ≥ 6 months
•
Number of subjects with anti-HBs seroconversion at any timepoint
•
For HBeAg-positive subjects (Part C only): number of subjects with HBeAg loss
and/or anti-HBe seroconversion at any timepoint


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 25 
27 MAR 2019 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 26 
27 MAR 2019 
4.
STUDY DESIGN
4.1. 
Treatment Plan and Regimen 
This is a randomized, double-blind, placebo-controlled study of VIR-2218 administered 
subcutaneously to healthy adult subjects and non-cirrhotic adult subjects with chronic HBV 
infection who are on NUC therapy. The study is designed to evaluate the safety, tolerability, PK, 
and antiviral activity of VIR-2218. Part A is planned to be conducted at 1 clinical investigative 
site; Parts B and C are planned to be conducted at multiple clinical investigative sites in the 
Asia-Pacific region. The study designs for Part A SAD and Part B/C MAD are presented in 
Figure 1 and Figure 2, respectively, and the cohort dosing schedule is provided in Appendix 6. 
Figure 1. 
SAD Study Design for Part A 
a Subject discharge will occur after all assessments are completed on Day 2 
Figure 2. 
MAD Study Design for Part B/C 
a Additional HBsAg monitoring is required for subjects with HBsAg levels with a > 10% decrease from the Day 1 
predose level at the Week 16 visit. Visits will occur every 4 weeks starting at Week 20 up to Week 48 or until 
the HBsAg level returns to > 90% of the Day 1 predose level. Additional HBsAg monitoring may be 
discontinued at the Sponsor’s discretion based on emerging data. 
4.1.1. 
Part A Single Ascending Dose Phase in Healthy Adult Subjects 
Healthy adult subjects will be enrolled in 1 of 4 planned ascending dose cohorts. At the start of 
each cohort, 2 sentinel subjects will be randomized 1:1 to VIR-2218 or placebo. These subjects 
will be dosed concurrently and monitored for 24 hours; if the investigator has no safety concerns, 
the remainder of the subjects in the same cohort will be dosed. Vital signs, symptom-directed 
physical examination(s), and AEs will be reviewed by the investigator prior to dosing any 
additional subjects. The remaining subjects will be randomized 5:1 to receive a single dose of 
VIR-2218 or placebo.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 27 
27 MAR 2019 
Subject screening will occur no more than 4 weeks prior to the Day 1 visit. Eligible subjects will 
be confined to the clinical investigative site on Day −1 to determine continued eligibility and for 
predose assessments. Subjects in each cohort will be randomized to receive VIR-2218 or placebo 
within 48 hours prior to study drug administration. Subjects will receive a single dose of study 
drug on Day 1 (VIR-2218 or placebo). Subjects will be discharged from the clinical investigative 
site after all assessments are completed on Day 2. 
Subjects will return to the clinical investigative site on an outpatient basis for safety, tolerability, 
and PK monitoring at specified timepoints through the last Post-dose Follow-up Visit (Week 12). 
Based on review of the accumulated, available data in Part A, the SRC may recommend dosing 
of 2 optional cohorts. In addition to the optional cohorts, up to 8 “floater” subjects for Part A 
may be added to any cohort, as determined and approved by the SRC (see Section 4.5.2 and 
Appendix 6 for further information).  
Fasting is not required for any study procedure/assessment. 
4.1.2. 
Part B/C Multiple Ascending Dose Phase in Non-Cirrhotic Adult Subjects with 
Chronic HBV Infection on Nucleoside/Nucleotide Therapy 
Non-cirrhotic adult subjects with chronic HBV infection on NUC therapy for ≥ 6 months will be 
enrolled in the Part B/C cohorts. Part B will enroll HBeAg-negative subjects. Part C will enroll 
HBeAg-positive subjects. Eligible subjects should have HBV DNA < 90 IU/mL. Each cohort in 
Part B/C will be composed of 4 subjects randomized 3:1 to VIR-2218 or placebo, respectively. 
There are 3 planned and 2 optional cohorts in Part B. There are 1 planned and 2 optional cohorts 
in Part C.  
Subjects enrolled in Part B/C of the study will remain outpatient. Subject screening will occur no 
more than 4 weeks prior to the Day 1 visit. Eligible subjects will undergo further assessments on 
Day 1 to qualify for study drug administration on Day 1. To exclude the presence of cirrhosis, 
screening will include a mandatory noninvasive assessment of liver fibrosis such as a FibroScan 
evaluation, unless the subject has results from a FibroScan evaluation performed within 6 months 
prior to screening or a liver biopsy performed within 1 year prior to screening that confirms the 
absence of Metavir F3 fibrosis or F4 cirrhosis.  
Subjects in each cohort will be randomized 3:1 to receive VIR-2218 or placebo within 48 hours 
prior to study drug administration on Day 1. Subjects will return to the clinical investigative site 
at Week 4 to receive a second dose of the same study drug administered on Day 1. The decision 
to administer a second dose will be made based on Week 3 laboratory values in accordance with 
dose suspension/stopping criteria in Section 4.6.  
Subjects will return to the clinical investigative site on an outpatient basis for safety, tolerability, 
PK, and antiviral activity monitoring at specified timepoints through the last Post-dose 
Follow-up Visit (Week 16). Additional HBsAg monitoring is required for subjects with HBsAg 
levels with a > 10% decrease from the Day 1 predose level at the Week 16 visit. Visits will occur 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 28 
27 MAR 2019 
every 4 weeks starting at Week 20 up to Week 48 or until the HBsAg level returns to > 90% of 
the Day 1 predose level. Additional HBsAg monitoring may be discontinued at the Sponsor’s 
discretion based on emerging data.  
Based on review of the accumulated, available data in Parts A, B, and C, the SRC may 
recommend dosing of optional cohorts following the same stratification. In addition to the 
optional cohorts, a combined total of up to 16 “floater” subjects for Part B/C may be added to 
any cohort, as determined and approved by the SRC (see Section 4.5.5 and Appendix 6 for 
further information). 
Fasting is not required for any study procedure/assessment. The assessments performed at each 
visit are described in Appendix 3 .  
4.2. 
Discontinuations 
Subjects who discontinue prematurely will be followed for safety, and under certain 
circumstances, subjects who discontinue study drug (as described in Section 4.3) may be 
replaced. If a subject discontinues from the study post-dose but before completion of the 
Week 12 visit for Part A or the Week 16 visit for Part B/C, an Early Termination (ET) visit 
should be performed. 
4.3. 
Replacement of Subjects 
Replacement subjects may be enrolled to ensure that the minimum data requirements for 
SRC dose escalation decisions and study progression are met, as described in Section 4.5. 
Subjects who do not receive the full planned dose, do not receive a second dose (for Part B/C), 
discontinue due to an AE that does not meet study progression/escalation and dose 
suspension/stopping rules (Section 4.6), or who withdraw from the study, may be replaced with 
confirmation by the SRC. Subjects who are discontinued from treatment for reasons other than 
experiencing an AE may be replaced following discussion between the Sponsor and investigator. 
The replacement subject will be assigned a unique study identification number and will receive 
the same study drug assignment and dose level as the subject who is being replaced and in the 
same blinded fashion. 
4.4. 
Safety Review Committee 
A SRC will perform ongoing reviews of safety, tolerability, and available study data collected 
throughout the study with the primary purpose of protecting the safety of subjects participating in 
this clinical study. The SRC will be governed by an SRC Charter that will be finalized prior to 
screening the first subject. 
The SRC will undertake safety data review prior to initiation of dosing a new cohort in Parts A, 
B, and C of the study in accordance with the SRC Charter. In addition, ad hoc SRC meetings 
may take place as needed, eg, for a significant safety event such as a subject or cohort stopping 
criterion being reached (Section 4.6). 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 29 
27 MAR 2019 
Decisions to suspend dosing or discontinue individual subjects from study drug will be made 
according to predetermined stopping rules (Section 4.6). Additionally, the SRC may recommend 
discontinuation of the study to the Sponsor. The SRC membership composition is described in 
detail in the SRC Charter. 
4.5. 
Study Drug Dosing, Study Progression, and Dose Escalation 
Progression rules are based on the absence of prespecified safety signals. Standard toxicity 
grading according to the current Common Terminology Criteria for Adverse Events (CTCAE) 
Version 5 will be used to grade AEs. The decision to enroll an optional cohort or expand an 
existing cohort will be made by the SRC based on available safety, tolerability, and antiviral 
activity data, if further data are considered necessary to better understand dose response and/or 
safety and tolerability.  
Subjects will receive VIR-2218 or placebo via SC injection according to the schedules provided 
in Appendix 2 and Appendix 3 for Cohort A and Cohort B/C, respectively.  
4.5.1. 
Part A Study Drug Dosing, Study Progression, and Dose Escalation in Planned 
Cohorts 
The starting dose for the first cohort in Part A is 50 mg, as described in Section 1.2.4. The SRC 
will review available laboratory and clinical safety data, including Week 4 data from the last 
available subject enrolled in the cohort to proceed to the next planned cohort in Part A. There are 
4 planned cohorts in Part A: 50 mg, 100 mg, 200 mg, and 400 mg (Table 4). 
4.5.2. 
Part A Optional Cohorts and Floater Subjects 
Based on SRC review of accumulated safety and tolerability data, 2 optional cohorts may be 
enrolled and dosed according to the same eligibility criteria and corresponding randomization 
scheme to better define safety and tolerability. The maximum optional dose in Part A will not 
exceed the defined maximum administered single dose of 900 mg (see Appendix 6 for additional 
information). 
In addition to the optional cohorts, up to 8 “floater” subjects in total for Part A may be added to 
expand any of 6 possible cohorts (planned or optional), as determined and approved by the SRC. 
Each expansion must include a minimum of 4 “floater” subjects, randomized 3:1 to VIR-2218 or 
placebo, furthermore only half of the total “floater” subjects (4 subjects in Part A) may enroll in 
the highest optional dose cohort. 
4.5.3. 
Part B Study Drug Dosing, Study Progression, and Dose Escalation in Planned 
Cohorts  
Overview: There are 3 planned cohorts in Part B: 50 mg, 100 mg, and 200 mg. Part B is limited 
to subjects with chronic HBV infection who are HBeAg-negative. Each cohort will receive a 
dose on Day 1, and a second dose at Week 4, such that the cumulative dose received for the 
planned cohorts in Part B will be 100 mg, 200 mg, and 400 mg (Table 4).  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 30 
27 MAR 2019 
Initiation of Part B: 2 dose levels in Part A (1a: 50 mg and 2a: 100 mg) must be completed and 
cumulative safety data, inclusive of the clinical and laboratory data from Week 4 from the last 
subject dosed in Cohort 2a (100 mg), must be reviewed by the SRC to begin dosing Part B (1b: 
50 mg).  
Escalation within Part B: Escalation to a higher dose-level cohort will only occur after the SRC 
has reviewed clinical and laboratory data including data from the Week 6 visit of the last 
available subject in the ongoing cohort, and the subject has completed their Week 8 visit. The 
SRC may review cumulative data from subjects in Parts A, B, and C at the time of meeting. The 
SRC will ensure that no subject in a cohort from Part B will receive a particular dose level prior 
to review of Week 4 data from subjects in Part A who have received at least the same cumulative 
dose level. 
4.5.4. 
Part C Study Drug Dosing, Study Progression, and Dose Escalation in Planned 
Cohorts 
Overview: There is 1 planned cohort in Part C: 200 mg (Cohort 3c). Escalations to higher dose 
levels may only occur in the optional cohorts (Section 4.5.5). Part C is limited to subjects with 
chronic HBV infection who are HBeAg-positive. This cohort will receive a dose on Day 1, and a 
second dose at Week 4, such that the cumulative dose received will be 400 mg (Table 4). 
Initiation of Part C: The planned Cohort 3c will initiate at the same time as Cohort 3b (200 mg, 
given as 2 doses, 4 weeks apart), after the SRC has reviewed clinical and laboratory data 
including from the Week 6 visit of the last available subject in Cohort 2b. Initiation of Cohort 3c 
will not occur until the last available subject in Cohort 2b has completed their Week 8 visit. 
4.5.5. 
Part B/C Optional Cohorts and Floater Subjects  
Based on SRC review of accumulated safety and tolerability data, up to 2 optional dose-level 
cohorts may be enrolled and dosed in each study part according to the randomization scheme to 
better define dose response and/or safety and tolerability. Enrollment of the Part B/C optional 
cohorts will be according to the same Part B/C eligibility criteria as the planned cohorts.  
The optional cohorts may be dosed at lower, intermediate, and/or higher dose levels than the 
dose levels explored in the planned Part B or C cohorts. The maximum cumulative dose level in 
any cohort in Part B or C will not exceed the highest single dose found to be well tolerated in 
Part A. For example, if a single dose of 900 mg in Part A is determined by the SRC to have an 
acceptable safety profile, dose levels of 450 mg (cumulative dose of 900 mg) or lower dose 
levels can be explored in Part B/C. The maximum administered cumulative dose in any cohort 
will not exceed 900 mg (Table 4). 
Dose escalation in the optional Part B/C cohorts will occur according to the same criteria as dose 
escalation within Part B (Section 4.5.3.) 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 31 
27 MAR 2019 
In addition to the optional cohorts, up to 16 “floater” subjects in total for Part B/C may be added 
to expand any Part B or C cohort (planned or optional), as determined and approved by the SRC. 
This “floater” pool is shared between Part B/C and the allocation of floater subjects does not 
need to be distributed evenly across parts. Subjects will be added in increments of 4 and 
randomized 3:1 to VIR-2218 or placebo, furthermore only half of the total “floater” subjects 
(8 total subjects in Part B/C) may enroll in the highest optional dose cohort. 
4.6. 
Stopping Rules 
The following stopping rules are based on potential safety signals. Standard toxicity grading 
according to the CTCAE Version 5.0 will be used to grade AEs. When a cohort is stopped, no 
further study drug will be administered at the dose level and further dose escalation/progression 
will be suspended. An ad hoc SRC meeting will be held, and only following SRC approval, may 
dosing be resumed at the same or a higher dose level; if required, additional approval from the 
concerned regulatory authority and the independent ethics committee (IEC)/institutional review 
board (IRB), in accordance with applicable requirements, will be obtained. De-escalation to a 
lower dose will be allowed at Sponsor discretion. 
4.6.1. 
Cohort Stopping Rules  
If any of the criteria described below are met, cohort dosing will be suspended or stopped: 
•
Part A only: If a sentinel subject experiences a VIR-2218-related Grade 3 or higher AE
•
If 1 or more subjects experience a Grade 3 VIR-2218-related rash
•
If 2 or more subjects experience the same VIR-2218-related Grade 3 or higher AE
•
If 1 or more subjects experience a VIR-2218-related serious adverse event (SAE)
•
If 1 or more subjects experiences a Grade 4 AE of rash, regardless of assessed causality
4.6.2. 
Individual Subject Stopping Rules in Part B/C 
Individual subjects in Part B/C who have received 1 dose of study drug will not receive a second 
dose if any the following criteria are met:  
•
Serum ALT > 10 × ULN
•
Serum ALT > 5 × ULN, with no change (< 50% of baseline) in HBsAg
•
Serum ALT or AST > 3 × ULN with a concomitant total bilirubin > 2 × ULN
•
Any clinical manifestations of hepatic decompensation


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 32 
27 MAR 2019 
5.
SUBJECT POPULATION
5.1. 
Number of Subjects and Subject Selection 
A total of up to 104 subjects are planned to complete this study, comprising up to 56 healthy 
adult subjects (Part A) and up to 48 non-cirrhotic adult subjects with chronic HBV infection on 
NUC therapy (Part B/C).  
•
Part A Planned/Optional Dose Cohorts: Up to 48 healthy subjects
o
Part A “Floater” Subjects: Up to 8 “floater” subjects may be added
•
Part B Planned/Optional Dose Cohorts: Up to 20 non-cirrhotic adult subjects with
chronic HBV infection that are HBeAg-negative on NUC therapy
•
Part C Planned/Optional Dose Cohorts: Up to 12 non-cirrhotic adult subjects with
chronic HBV infection that are HBeAg-positive on NUC therapy
o
Part B/C “Floater” Subjects: Up to 16 “floater” subjects may be added
5.2. 
Part A Inclusion Criteria 
Each subject must meet all the following inclusion criteria at screening to be eligible for 
enrollment in the study: 
1. Age 18 (or age of legal consent, whichever is older) to 55 years
2. 12-lead electrocardiogram (ECG) within normal limits; or, with no clinically significant
abnormalities at screening, as determined by the clinical investigator.
3. Female subjects must have a negative pregnancy test or confirmation of post-
menopausal status. Post-menopausal status is defined as age > 50 years with no menses
for at least 2 years. Women of child-bearing potential (WOCBP) must have a negative
serum pregnancy test at screening and a negative urine pregnancy test on Day -1, cannot
be breast feeding, and must be willing to use highly effective methods of contraception
14 days before study drug administration through 12 weeks after study drug
administration. Refer to Section 6.6 for more information on highly effective methods of
contraception.
4. Male subjects with female partners of child-bearing potential must agree to meet 1 of the
following contraception requirements from the time of study drug administration until
the last follow-up visit: vasectomy with documentation of azoospermia, or male condom
use plus partner use of 1 of the contraceptive options listed for contraception for
WOCBP. Male subjects must also agree to not donate sperm for the 12 weeks following
study drug administration. Refer to Section 6.6 for more information on highly effective
methods of contraception.
5. Agrees not to donate blood during the duration of the study


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 33 
27 MAR 2019 
6. Willing to comply with the study requirements and able to provide written informed
consent
7. Body mass index (BMI) ≥ 18.0 kg/m2 and ≤ 32 kg/m2
8. Agree to not increase physical activity for 4 weeks after study drug administration
5.3. 
Part A Exclusion Criteria 
Each subject must not meet any of the following exclusion criteria to be eligible for enrollment 
in the study: 
1. Any clinically significant chronic medical condition that, in the opinion of the
investigator, makes the volunteer unsuitable for participation in the study
2. Any clinically significant acute condition such as fever (> 38oC) or acute respiratory
illness within 7 days of study drug administration
3. Receipt of a vaccine 14 days prior to Day 1
4. Previous or current psychiatric condition that precludes compliance with the protocol.
Specifically excluded are persons with psychoses, ongoing risk for suicide, or history of
suicide attempt or gesture within the past 5 years
5. Systolic blood pressure > 140 mmHg and a diastolic blood pressure of > 90 mmHg after
approximately 10 minutes resting at screening
6. Subject has the following laboratory parameters at screening:
a.
ALT, AST, creatinine or total bilirubin above the upper limit of normal (ULN)
b. hemoglobin (Hgb), absolute neutrophil count (ANC), platelets, or albumin below the
lower limit of normal (LLN)
c.
white blood cells (WBC), potassium (K), or sodium (Na) above the ULN or below the
LLN
Study laboratory tests may be repeated once (eg, for values thought to be erroneous) 
with Sponsor medical monitor approval. 
7. Received an investigational agent within 90 days before study drug administration or are
active in the follow-up phase of another clinical study involving interventional
treatment. Subjects must also agree not to take part in any other study at any time during
their participation in this study, inclusive of the follow-up period.
8. Laboratory evidence of active infection with human immunodeficiency virus (HIV),
hepatitis C virus (HCV), or HBV
9. Consume more than 7 units of alcohol per week (unit: 1 glass of wine
[125 mL] = 1 measure of spirits [30 mL] = one-half pint of beer [284 mL]). Alcohol is
limited to no more than 1 unit per day for the duration of the study
10. History or clinical evidence of alcohol or drug abuse, within the 12 months before
screening or a positive drug screen for amphetamines, cocaine, methadone, or opiates at
screening unless it can be explained by a prescribed medication; the diagnosis and
prescription must be approved by the investigator.


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 34 
27 MAR 2019 
11. Known hypersensitivity or contraindication to an siRNA or GalNAc
12. History of intolerance to SC injection
13. Any conditions which, in the opinion of the investigator, would make the subject
unsuitable for enrollment or could interfere with the subject’s participation in or
completion of the study
14. Donated more than 500 mL of blood within 90 days before study drug administration
15. Creatinine clearance (CLcr) < 90 mL/min as calculated by the Cockcroft-Gault formula
at screening
16. Used prescription drugs within 14 days before study drug administration except for a
stable dose of: medication to treat hypertension, inhaler or nebulizer to treat asthma,
hormone replacement therapy, antihistamines, and contraceptive therapy (refer to
Section 6.4.1 for more information). Hypertension must be well controlled on 1
medication (two active components in one medication is permitted) for > 6 months.
Asthma must be well controlled, requiring, on average, use of a rescue bronchodilator no
more than twice per week.
17. Use of over-the-counter (OTC) medication or herbal remedy within 14 days before study
drug (≤ 2g/day of paracetamol (acetaminophen), ≤ 3g/day of aspirin or < 1.2 g/day of
ibuprofen is permitted) and throughout the study.
5.4. 
Part B/C Inclusion Criteria 
Each subject must meet all the following inclusion criteria at screening to be eligible for 
enrollment in the study: 
1. Age 18 (or age of legal consent, whichever is older) to 65 years at the time of screening
2. 12-lead ECG within normal limits; or, with no clinically significant abnormalities at
screening, as determined by the clinical investigator
3. Female subjects must have a negative pregnancy test or confirmation of post-
menopausal status. Post-menopausal status is defined as age > 50 years with no menses
for at least 2 years at the time of screening. WOCBP must have a negative serum
pregnancy test (using central laboratory) at screening and a negative urine pregnancy
test on Day 1, cannot be breast feeding, and must be willing to use highly effective
methods of contraception 14 days before study drug administration through 12 weeks
after last study drug administration. Refer to Section 6.6 for more information on highly
effective methods of contraception.
4. Male subjects with female partners of child-bearing potential must agree to meet 1 of the
following contraception requirements from the time of study drug administration until
the last follow-up visit: vasectomy with documentation of azoospermia, or male condom
use plus partner use of 1 of the contraceptive options listed for contraception for
WOCBP. Male subjects must also agree not to donate sperm for the 12 weeks following
last study drug administration. Refer to Section 6.6 for more information on highly
effective methods of contraception.


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 35 
27 MAR 2019 
5. Agrees to not donate blood during the duration of the study
6. Willing to comply with the study requirements and able to provide written informed
consent
7. BMI ≥ 18.0 kg/m2 and ≤ 32 kg/m2
8. Chronic HBV infection as defined by a positive serum HBsAg for ≥ 6 months
9. On NUC therapy for at least 6 months without an interruption of 7 or more consecutive
days
10. HBsAg > 150 IU/mL (by central laboratory)
11. HBV DNA < 90 IU/mL (by central laboratory)
12. Serum ALT and AST ≤ 2 × ULN (by central laboratory)
13. Agrees not to increase physical activity for 4 weeks after each study drug administration
5.5. 
Part B/C Exclusion Criteria 
1. Any clinically significant chronic medical condition other than chronic HBV infection
that, in the opinion of the investigator makes the volunteer unsuitable for participation in
the study
2. Any clinically significant acute condition such as fever (> 38oC) or acute respiratory
illness within 7 days of study drug administration
3. Significant fibrosis or cirrhosis as defined by having either a FibroScan result
of > 8.5kPa at screening or a liver biopsy within 1 year with Metavir F3 fibrosis or F4
cirrhosis. Refer to Section 7.2.9 for more information.
4. Receipt of a vaccine 14 days prior to Day 1
5. Previous or current psychiatric condition that precludes compliance with the protocol.
Specifically excluded are persons with psychoses, ongoing risk for suicide, or history of
suicide attempt or gesture within the past 5 years
6. Systolic blood pressure > 140 mmHg and a diastolic blood pressure of > 90 mmHg after
approximately 10 minutes resting at screening
7. Subject has the following laboratory parameters at screening by central laboratory:
a.
creatinine, total bilirubin, INR or prothrombin time above the ULN
b. hemoglobin, ANC, platelets, or albumin below the LLN
c.
WBC, potassium, or sodium above the ULN or below the LLN
d. serum ALT or AST > 2 × ULN
Study laboratory tests may be repeated once (eg, for values thought to be erroneous)
with Sponsor approval.
8. Received an investigational agent within 90 days before study drug administration or are
active in the follow-up phase of another clinical study involving interventional
treatment. Subjects must also agree not to take part in any other study at any time during
their participation in this study, inclusive of the follow-up period.


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 36 
27 MAR 2019 
9. Used prescription drugs within 14 days before study drug administration except for a
stable dose of: medication to treat hypertension, inhaler or nebulizer to treat asthma,
hormone replacement therapy, antihistamines, and contraceptive therapy (refer to
Section 6.4.1 for more information). Hypertension must be well controlled on no more
than 2 medications or 1 medication with two active components for > 6 months. Asthma
must be well controlled, requiring, on average, use of a rescue bronchodilator no more
than twice per week.
10. Use of over-the-counter (OTC) medication or herbal remedy within 14 days before study
drug and throughout the study, with the following exceptions of permitted OTC
medications: Paracetamol (acetaminophen) ≤ 2g/day, aspirin ≤ 3g/day or ibuprofen
< 1.2 g/day.
11. Active infection with HIV, HCV or hepatitis Delta virus as determined by the central
laboratory
12. Consume more than 7 units of alcohol per week (unit: 1 glass of wine
[125 mL] = 1 measure of spirits [30 mL] = one-half pint of beer [284 mL]). Alcohol is
limited to no more than 1 unit per day for the duration of the study
13. History or clinical evidence of alcohol or drug abuse, within the 12 months before
screening or a positive drug screen for amphetamines, cocaine, methadone or opiates at
screening unless it can be explained by a prescribed medication; the diagnosis and
prescription must be approved by the investigator. Screening results must be reviewed
by the investigator to confirm eligibility prior to dosing.
14. Known hypersensitivity or contraindication to an siRNA or GalNAc
15. History of intolerance to SC injection
16. Any conditions which, in the opinion of the investigator, would make the subject
unsuitable for enrollment or could interfere with the subject’s participation in or
completion of the study
17. Donated more than 500 mL of blood within 90 days before study drug administration
18. CLcr < 60 mL/min as calculated by the Cockcroft-Gault formula at screening
19. History of chronic liver disease from any cause other than chronic HBV infection
20. History of hepatic decompensation, including ascites, hepatic encephalopathy and/or
esophageal or gastric varices


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 37 
27 MAR 2019 
6.
INVESTIGATIONAL MEDICINAL PRODUCTS
6.1. 
Randomization, Blinding, and Treatment Codes 
An Interactive Web Response System (IWRS) will be employed to manage subject 
randomization and treatment assignments.  
6.1.1. 
Procedures for Breaking of Treatment Codes 
Blinding of study treatment will be managed by the clinical investigative site’s pharmacy in 
accordance with the Pharmacy Manual. In the event of a medical emergency where breaking the 
blind is required to provide medical care to the subject, the investigator may obtain treatment 
assignment for that subject. IWRS should be used as the primary method of breaking the blind. If 
IWRS cannot be accessed, the investigator should contact the Sponsor medical monitor to break 
the blind. Treatment assignment should remain blinded unless that knowledge is necessary to 
guide subject emergency medical care. The investigator is requested to contact the Sponsor 
medical monitor promptly in case of any treatment unblinding. 
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by the subject. 
The Sponsor or designee may independently unblind cases for expedited reporting of suspected 
unexpected serious adverse reactions (SUSARs) as required by regulators. 
6.2. 
Description and Handling of VIR-2218 and Placebo 
6.2.1. 
Formulation 
VIR-2218 is a clear, colorless to pale yellow solution, which will be supplied by the Sponsor as a 
sterile solution for subcutaneous injection at a free acid concentration of 200 mg/mL. Placebo is 
a sterile, preservative-free normal saline 0.9% solution for SC injection, which will be supplied 
by the clinical investigative site or the Sponsor where required. 
6.2.2. 
Packaging and Labeling 
VIR-2218 (solution for SC injection) is packaged in 2-mL glass vials with a fill volume of no 
less than 0.7 mL to allow for complete withdrawal of 0.5 mL of drug product at the pharmacy. 
The container closure system consists of a Type I glass vial, a Teflon-faced 13-mm stopper, and 
a flip-off aluminum seal. 
6.2.3. 
Storage and Handling 
Study drug may be dispensed only by the investigator, by a staff member specifically authorized 
by the investigator, or by pharmacy staff, as appropriate. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 38 
27 MAR 2019 
Each clinical investigative site will be responsible for assembly and labeling of injection 
syringe(s) according to procedures detailed in the Pharmacy Manual. The pharmacy staff will 
prepare the study drug using an aseptic technique. The amount (in mg) of study drug to be 
administered will be determined based on the assigned dose level for the cohort for healthy 
subjects and subjects with chronic HBV infection. All syringes will be covered to ensure the 
study blind is maintained since the IP solution may have a slight yellow coloring and the placebo 
(sterile normal saline) is clear. Additional details regarding the procedure for preparing study 
drug, the volume to be loaded into each syringe, and how the syringes are to be ‘blinded’ are 
provided in the Pharmacy Manual. 
No special procedures for the safe handling of VIR-2218 are required. Study drug will be stored 
upright and refrigerated at 2 to 8°C protected from light in the storage area of the clinical 
investigative site pharmacy, in a secure, temperature-controlled, locked environment with 
restricted access. Any deviation from the recommended storage conditions should be reported to 
the Sponsor and use of the study drug halted until authorization for its continued use has been 
provided by the Sponsor or designee. Refer to the Pharmacy Manual for additional storage 
details.  
6.2.4. 
 Dosage and Administration of VIR-2218 
Dose and dose cohorts for this study are described in Sections 1.2.4 and 4.1, respectively. Study 
drug dose and administration are summarized by dose cohort in Table 4. On dosing days, the 
pharmacist or designee will withdraw the required amount of study drug into 1 or more syringes 
containing up to 1.5 mL/per syringe. A qualified clinical investigative site staff member under 
the supervision of the investigator or designee will administer study drug to subjects via SC 
injection. The injection site(s) will be marked and mapped for later observation, and should be 
documented. If a local reaction around the injection site occurs, photographs may be obtained. 
Refer to the Pharmacy Manual for detailed study drug preparation and administration 
instructions.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 39 
27 MAR 2019 
Table 4. 
Study Drug Dose and Administration 
Cohort 
Visit Dose 
Level 
(mg) 
Visit Dose 
Volume 
(mL) 
Cumulative 
Dose (mg) 
Injections Per 
Dose 
Administration 
Injections 
Total 
Cumulative 
Dose Volume 
(mL)a 
1a 
50 
0.25 
50 
1 
1 
0.25 
2a 
100 
0.50 
100 
1 
1 
0.50 
3a 
200 
1.0 
200 
1 
1 
1.0 
4a 
400 
2.0 
400 
2 
2 
2.0 
Optional 5a 
< 900 
< 4.5 
< 900 
3 
3 
< 4.5 
Optional 6a 
< 900 
< 4.5 
< 900 
3 
3 
< 4.5 
1b 
50 
0.25 
100 
1 
2 
0.50 
2b 
100 
0.50 
200 
1 
2 
1.0 
3b 
200 
1.0 
400 
1 
2 
2.0 
Optional 4b 
< 300 
< 1.5 
< 600 
1 
2 
< 3 
Optional 5b 
< 450 
< 2.25 
< 900 
2 
4 
< 4.5 
3c 
200 
1.0 
400 
1 
2 
2.0 
Optional 4c 
< 300 
< 1.5 
< 600 
1 
2 
< 3 
Optional 5c 
< 450 
< 2.25 
< 900 
2 
4 
< 4.5 
a Injection volume per site will not exceed 1.5mL 
6.3. 
Investigational Product Accountability 
The investigator or designee will maintain accurate records of receipt and the condition of the 
study drug supplied for this study, including but, not limited to, date of receipt, quantity, and 
temperature. In addition, accurate records will be kept of when and how much study drug is 
dispensed and administered to each subject in the study. Any reasons for departure from the 
protocol dispensing regimen must also be recorded. 
At the completion of the study, there will be a final reconciliation of all study drugs.  
Further instructions about drug accountability and disposal are detailed in the Pharmacy Manual. 
6.4. 
Concomitant Therapy 
6.4.1. 
Permitted Concomitant Medications 
For Part A, B, and C the following medications/treatments are permitted: 
•
Hormone replacement therapy


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 40 
27 MAR 2019 
•
Oral, injectable, subdermal, intravaginal, or implantable contraceptives, as well as
intrauterine device, and intrauterine hormone-releasing system are permitted for
contraception
•
Prescription drugs necessary to treat hypertension. Hypertension must be well
controlled (on a stable dose of no more than 2 medications or 1 medication with two
active components for > 6 months)
•
Paracetamol (≤ 2g/day), aspirin (≤ 3g/day), or ibuprofen (< 1.2 g/day)
•
Antihistamines
•
Prescription inhaler or nebulizer to treat asthma (inhaled bronchodilator or inhaled
steroid). Asthma must be well controlled, defined as historical use of a rescue
bronchodilator on average no more than twice per week.
6.4.2. 
Prohibited Concomitant Medications 
For Part A, B, and C the following medications/treatments are prohibited: 
•
Any OTC medications or herbal remedy within 14 days before of study drug
administration except for those specified in Section 6.4.1
•
Any prescription medications within 14 days before study drug administration except
for those specified in Section 6.4.1 and NUC therapy for Part B/C subjects
6.5. 
NUC Therapy 
Examples of allowed NUC therapy are listed below, but not limited to: 
•
Tenofovir (at recommended dose for the given formulation)
•
Entecavir
•
Lamivudine
•
Adefovir/adefovir dipivoxil
6.6. 
Contraceptive Requirements
WOCBP may be included in this study and include any female subject who has experienced 
menarche and who is not post-menopausal or permanently sterilized (eg, bilateral tubal 
occlusion, hysterectomy, or bilateral salpingectomy). 
WOCBP must be willing to use highly effective methods of contraception 14 days before dose, 
throughout study participation, and for 12 weeks after last dose of study drug administration. 
Highly effective methods of birth control result in a low failure rate (ie, less than 1% per year). 
Birth control methods which are considered highly effective include: 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 41 
27 MAR 2019 
•
Established use of combined (estrogen and progestogen containing) oral, intravaginal,
or transdermal hormonal methods of contraception associated with inhibition of
ovulation OR established use of progestogen-only oral, injectable, or implantable
hormonal methods of contraception associated with inhibition of ovulation. It is not
currently known whether VIR-2218 will impact the effectiveness of hormonal
contraceptive methods; therefore, it is recommended to use an additional form of
contraception (ie, barrier method) throughout the study and for 12 weeks after last
study drug administration.
•
Placement of an intrauterine device
•
Placement of an intrauterine hormone-releasing system
•
Surgical sterilization of male partner (with the appropriate post-vasectomy
documentation of the absence of sperm in the ejaculate; for female subjects on the
study, the vasectomized male partner should be the sole partner for that subject)
•
True sexual abstinence, when in line with the preferred and usual lifestyle of the
subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation
methods) and withdrawal are not acceptable methods of contraception. Abstinent
subjects have to agree to use 1 of the above-mentioned contraceptive methods, if they
start sexual relationships during the study and for up to 12 weeks after last dose of
study drug administration, or for as long as the subject is followed on study,
whichever is longer.
•
Barrier method in combination with hormonal contraceptive, as described above
Post-menopausal status is defined as no menses for 24 months in subjects > 50 years of age. 
Male subjects with female partners of child-bearing potential must agree to meet 1 of the 
following contraception requirements from the time of study treatment administration until the 
last follow-up visit. 
•
Vasectomy with documentation of azoospermia
•
Male condom plus partner use of 1 of the contraceptive options listed above for
contraception for WOCBP (hormonal contraceptive, intrauterine device)
Male subjects must also agree not to donate sperm for the 12 weeks following last study drug 
administration.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 42 
27 MAR 2019 
7.
STUDY PROCEDURES
7.1. 
Procedures and Specifications 
The Schedule of Study Assessments is provided in Appendix 2 for Part A and Appendix 3 for 
Part B/C. Unscheduled visits are permitted at the discretion of the investigator as needed for 
safety assessment. 
7.1.1. 
Medical History 
A complete medical history, including details regarding illnesses and allergies, date(s) of onset, 
and whether condition(s) is currently ongoing, medication history, including prior HBV 
treatment history (Part B/C only) and HBV genotype history (if available; Part B/C only), will be 
collected on all subjects during screening and should be updated prior to dosing.  
7.1.2. 
Assessment of Antiviral Activity and Development of Resistance 
During Part B/C, assessments of antiviral activity will include: HBsAg, HBeAg, 
, anti-
HBs, anti-HBe, HBV DNA, 
, and assessment of HBV and NUC resistance if 
indicated. HBV genome will be sequenced and analyzed for mutations that can confer resistance 
to VIR-2218 and NUCs in subjects with confirmed HBV breakthrough as defined by 
HBV DNA ≥ 500 IU/mL measured at 2 consecutive study visits. Details regarding the 
processing, shipping, and analysis of the samples are provided in the Laboratory Manual. 
7.1.3. 
Screening Viral Serology Parameters 
Screening viral serology parameters are as follows: 
•
Part A: Active infection with HIV infection, HCV infection, and HBV infection.
•
Part B/C: Active infection with HIV infection, HCV infection, chronic HBV infection and
hepatitis Delta virus infection. Chronic HBV infection is defined as serum HBsAg for > 6
months. In cases of occult HBV, chronic HBV infection is defined as serum HBV DNA
positive for > 6 months.
7.1.4. 
Pharmacokinetic Assessments 
Blood and urine samples will be collected to assess concentrations of VIR-2218 and metabolites, 
as applicable. Detailed schedules of timepoints for the collection of samples for VIR-2218 PK 
analysis for Part A of the study are provided in Appendix 4. Timepoints for the collection of 
samples for VIR-2218 PK analysis for Part B/C of the study are provided in Appendix 5.  
Details regarding the processing, shipping, and analysis of the samples are provided in the 
Laboratory Manual. 
CCI
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 43 
27 MAR 2019 
7.2. 
Safety Assessments 
The assessment of safety during the study will consist of the surveillance and recording of AEs 
including SAEs, recording of concomitant medications, physical examination findings, alcohol 
assessment, ECG, and laboratory tests. All AEs related to screening activities must be collected 
from the time of consent onwards; any other events occurring during the screening period should 
be reported as medical history. All SAEs must be collected from the time of consent onwards. 
7.2.1. 
Physical Examination 
A full physical examination will include general appearance, head, neck, chest/respiratory, 
heart/cardiovascular, gastrointestinal/liver, extremities, skin, and screening neurological 
assessments. 
A symptom-directed physical examination will be performed according to investigator 
discretion. 
7.2.2. 
Alcohol Assessment 
Alcohol intake during the study will be recorded. 
7.2.3. 
Height and Weight 
Height and body weight will be measured. Body mass index will be calculated from height and 
weight. 
7.2.4. 
Vital Signs 
Vital sign measurements include blood pressure, pulse rate, temperature (oral preferred), and 
respiratory rate. Vital signs should be measured after the subject has rested comfortably for 
approximately 10 minutes. When scheduled at the same timepoints, the assessments of vital 
signs and 12-lead ECGs must be performed first, before the physical examinations, blood sample 
collections, and urine collections. 
7.2.5. 
Electrocardiogram 
Safety ECGs: 12-lead safety ECGs will be recorded and reviewed on-site by the investigator as 
outlined in Appendix 2 and Appendix 3. Specified collection timepoints for each visit are 
provided in Appendix 4 and Appendix 5.  
Cardiodynamic ECG evaluation (Part A only): (12-lead ECGs extracted from continuous Holter 
recordings): Up to 10 replicate ECGs may be extracted by the central ECG core laboratory at 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 44 
27 MAR 2019 
timepoints provided in Appendix 4 and Appendix 5. Subjects will be resting supine for at least 
10 minutes prior to and 5 minutes after each nominal time point. 12-lead ECGs will be extracted 
from the 5-minute time window following the nominal time point. When scheduled at the same 
time points, the assessments of vital signs and 12-lead ECGs should be performed first, before 
the physical examinations, blood sample collections, and urine collections.  
In Part A, the 12-lead Holter and ECG equipment will be supplied and supported by the central 
ECG core laboratory. All cardiodynamic ECG data will be collected using a Global 
Instrumentation M12R ECG continuous 12-lead digital recorder. The continuous 12-lead digital 
ECG data will be stored onto SD memory cards. ECGs to be used in the analyses may be 
selected by pre-determined time points as defined in Appendix 4 and Appendix 5, and 
cardiodynamic ECGs will be stored and  may be read by the central ECG core laboratory. 
The following principles will be followed in the central ECG core laboratory: 
• ECG analysts are blinded to the subject, visit, and treatment allocation 
• Baseline and on-treatment ECGs for a particular subject will be over-read on the same 
lead and will be analyzed by the same reader 
• The primary analysis lead is lead II.  If lead II is not analyzable, then primary lead of 
analysis will be changed to another lead for the entire subject data set. 
The following is a brief description of ECG analysis methods utilized by the central ECG core 
laboratory. 
TQT Plus ECG Extraction Technique 
Ten 14-second digital 12-lead ECG tracings may be extracted from the continuous Holter 
recordings using the ‘TQT Plus method’, a computer-assisted and statistical process utilized by 
the central ECG core laboratory. The method enables extraction of ECGs with the lowest HR 
variability and noise within the protocol-specified extraction time window (eg, the HR and QT 
changes from beat-to-beat in the range of < 10%). At each protocol-specified timepoint, 10 ECG 
replicates may be extracted from a 5-minute “ECG window” (typically, the last 5 minutes of the 
15-minute period when the subject is maintained in a supine or semi-recumbent quiet position). 
Expert-Precision QT Analysis 
Expert-precision QT analysis may be performed on all analyzable (non-artifact) beats in the 10 
ECG replicates.  Statistical quality control procedures are used to review and assess all beats and 
identify “high” and “low” confidence beats using several criteria, including: 
• QT or QTc values exceeding or below certain thresholds (biologically unlikely). 
• RR values exceeding or below certain thresholds (biologically unlikely). 
• Rapid changes in QT, QTc or RR from beat to beat. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 45 
27 MAR 2019 
Measurements of all primary ECG parameters (QT, QTc, RR) in all recorded beats of all 
replicates that are deemed “high confidence” are performed using COMPAS software. All 
low-confidence beats are reviewed manually and adjudicated using pass-fail criteria.  The final 
QC assessment is performed by a cardiologist. The beats found acceptable by manual review are 
included in the analysis. The median QT, QTc, and RR value from each extracted replicate is 
calculated, and then the mean of all available medians from a nominal timepoint is used as the 
subject’s reportable value at that timepoint. 
T-wave morphology categories are presented in Table 5. Categorical T-wave morphology
analysis and the measurement of PR and QRS intervals will be performed manually in 3 of the
10 ECG replicates at each timepoint. Each fiducial point (onset of P-wave, onset of Q-wave,
offset of S-wave, and offset of T-wave) is electronically marked.
In addition to the T-wave categorical analysis, the presence of abnormal U-waves is noted. 
Table 5.  
T-Wave Morphology Categories (Assessed Manually) 
Category 
Description 
Normal T-wave 
Any T-wave not meeting any criterion below 
Flat T-waves 
T amplitude < 1 mm (either positive or negative) including flat isoelectric line 
Notched T-wave (+) 
Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of 
the positive T-wave 
Biphasic 
T-wave that contains a second component with an opposite phase that is at least 0.1 mV
deep (both positive and negative/positive and polyphasic T-waves included)
Normal T-wave (-) 
T amplitude that is negative, without biphasic T-wave or notches 
Notched T-wave (-) 
Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of 
the negative T-wave 
7.2.6. 
Pregnancy Testing 
A pregnancy test or confirmation of post-menopausal status must be confirmed for all female 
subjects. Post-menopausal status is defined as age > 50 years with no menses for at least 2 years 
at the time of screening. Pregnancy tests will be performed for WOCBP only. Pregnancy testing 
will be performed per the schedule of assessments (SoA) and any time pregnancy is suspected. A 
WOCBP who is known to be pregnant or who does not have a negative pregnancy test at 
screening is not eligible for study participation. A serum pregnancy test will be performed at 
screening and urine pregnancy tests will be performed thereafter. During the study, the results of 
these pregnancy tests must be known prior to study drug administration. A WOCBP determined 
to be pregnant while on study will be followed until the pregnancy outcome is known, as 
described in Section 8.5.2.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 46 
27 MAR 2019 
7.2.7. 
Clinical Laboratory Assessments 
Clinical laboratory tests that will be performed in this study are presented in Table 6. In the event 
of an unexplained clinically relevant abnormal laboratory test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the investigator 
until it has returned to the normal range or stabilized, and/or a diagnosis is made to adequately 
explain the abnormality. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 47 
27 MAR 2019 
Table 6. 
Clinical Laboratory Tests 
Hematology 
 
• 
Complete blood count with differential 
 
Chemistry 
 
• 
Albumin 
• 
Creatinine clearance 
• 
Blood urea nitrogen (BUN) 
• 
Gamma glutamyl transferase (GGT) 
• 
Calcium 
• 
Glucose 
• 
Carbon dioxide/bicarbonate 
• 
Lactate dehydrogenase (LDH) 
• 
Chloride 
• 
Potassium 
• 
Creatine kinasea 
• 
Sodium 
• 
Creatinine 
• 
Uric acid 
Liver Function Tests 
 
• 
Alkaline phosphatase (ALP)  
• 
AST 
• 
ALT 
• 
Bilirubin (total and direct) 
Coagulation Parameters 
 
• 
International normalized ratio (INR) time  
• 
Prothrombin 
Urinalysis 
 
• 
Bilirubin 
• 
Proteins 
• 
Glucose 
• 
Red blood cells (RBCs) 
• 
Ketones 
• 
Screen for drugs of abuse 
• 
Leukocytes 
• 
Specific gravity 
• 
Microscopy (if clinically indicated) 
• 
Urobilinogen 
• 
Nitrite 
• 
Visual inspection for appearance and color 
• 
pH  
 
Pregnancy Testing 
 
• 
Beta-human chorionic gonadotropin (WOCBP only) • 
Urine pregnancy test 
Serology 
 
• 
Hepatitis B, C, and Delta 
• 
Human immunodeficiency virus I and II 
a Only required if ALT and/or AST is elevated 2 × higher than predose Day 1 baseline value 
 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 48 
27 MAR 2019 
7.2.8. 
FibroScan 
To exclude the presence of cirrhosis, subjects in Part B/C will have a FibroScan evaluation, 
unless the subject has results from a FibroScan evaluation performed within 6 months prior to 
screening or liver biopsy performed within 1 year prior to screening that confirm the absence of 
Metavir F3 fibrosis or F4 cirrhosis. If a subject has had both procedures in the specified 
timeframes, the most recent result should be used to determine eligibility. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 49 
27 MAR 2019 
8. 
ADVERSE EVENTS MANAGEMENT 
8.1. 
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events 
8.1.1. 
Adverse Events 
An adverse event is any untoward medical occurrence in a clinical study subject administered a 
medicinal product, which does not necessarily have a causal relationship with the treatment. 
An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product. AEs may also include pre- or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Pre-existing conditions (recorded as medical history), which change in 
nature or severity should also be considered AEs.  
An AE does not include the following: 
• Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and 
transfusion. The condition that led to the procedure may be an adverse event and must be 
reported. 
• Pre-existing diseases, conditions, or laboratory abnormalities present or detected before 
the screening visit that do not worsen 
• Situations where an untoward medical occurrence has not occurred (eg, hospitalization 
for elective surgery, social and/or convenience admissions) 
• Overdose of study drug without clinical sequelae 
• Any medical condition or clinically significant laboratory abnormality with an onset date 
before the consent form is signed and not related to a protocol-associated procedure is not 
an AE. It is considered to be pre-existing and should be documented on the medical 
history CRF (Case Report Form). 
• Unless associated with signs or symptoms, laboratory abnormalities (eg, low platelets) 
should not be recorded as AEs, as these abnormalities will be captured as laboratory 
abnormalities 
• Procedures should not be recorded as AEs; however, the condition that led to the 
procedure may be an AE 
8.1.2. 
Serious Adverse Events 
An SAE is any event that results in the following: 
• Death 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 50 
27 MAR 2019 
•
Life-threatening: An AE is life threatening if the subject was at immediate risk of death
from the event as it occurred; ie, it does not include a reaction that if it had occurred in a
more serious form might have caused death. For example, drug induced hepatitis that
resolved without evidence of hepatic failure would not be considered life threatening
even though drug induced hepatitis can be fatal.
•
Inpatient hospitalization or prolongation of existing hospitalization: AEs requiring
hospitalization should be considered SAEs. Hospitalization for elective surgery or routine
clinical procedures that are not the result of AE (eg, elective surgery for a pre-existing
condition that has not worsened) need not be considered AEs or SAEs. If anything
untoward is reported during the procedure, that occurrence must be reported as an AE,
either 'serious' or 'non-serious' according to the usual criteria. In general, hospitalization
signifies that the subject has been detained (usually involving at least an overnight stay)
at the hospital or emergency ward for observation and/or treatment that would not have
been appropriate in the physician's office or outpatient setting. When in doubt as to
whether 'hospitalization' occurred or was necessary, the AE should be considered serious.
•
Persistent or significant disability/incapacity: an AE is incapacitating or disabling if the
experience results in a substantial and/or permanent disruption of the subject's ability to
carry out normal life functions
•
Congenital anomaly/birth defect in the offspring of a subject who received VIR-2218
Other: Important medical events that may not result in death, be life-threatening, or require 
hospitalization, may be considered an SAE when, based upon appropriate medical judgment, 
they may jeopardize the subject and may require medical or surgical intervention to prevent one 
of the outcomes listed in this definition. Examples of such events are: 
•
Intensive treatment in an emergency room or at home for allergic bronchospasm
•
Blood dyscrasias or convulsions that do not result in inpatient hospitalization
•
Development of drug dependency or drug abuse
8.1.3. 
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events 
Per Section 8.1.1, laboratory abnormalities without an associated AE (signs or symptoms) and/or 
which do not require medical intervention, are not themselves recorded as AEs or SAEs. 
However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that 
require medical or surgical intervention must be recorded as an AE, as well as an SAE, if 
applicable. In addition, laboratory or other abnormal assessments (eg, electrocardiogram, vital 
signs) that are associated with signs and/or symptoms must be recorded as an AE or SAE if they 
meet the definition of an AE or SAE as described in Sections 8.1.1 and 8.1.2. If the laboratory 
abnormality is part of a clinical syndrome, record the syndrome or diagnosis (eg, anemia), not 
the laboratory result (ie, decreased hemoglobin). 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 51 
27 MAR 2019 
8.2. 
Assessment of Adverse Events and Serious Adverse Events 
The investigator or qualified sub-investigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments. 
8.2.1. 
Assessment of Causality for Study Drugs and Procedures 
Causality (Yes or No) should be determined by the investigator or qualified sub-investigator. An 
answer of Yes, should be entered when, in their opinion, there is either (a) a reasonable 
possibility that the AE is associated with study drug or (b) no reasonable alternative explanation 
can be identified. Otherwise, causality to study drug should be categorized as No. A mere 
possibility of a causal relationship is not grounds for a Yes categorization. 
8.2.2. 
Assessment of Severity 
AE severity should be graded using the CTCAE Version 5.0. 
8.3. 
Investigator Requirements and Instructions for Reporting Adverse Events and 
Serious Adverse Events to Vir 
Requirements for collection prior to study drug initiation: 
After informed consent, but prior to initiation of study medication, the following types of events 
should be reported: AEs related to protocol-mandated procedures and all SAEs. 
Adverse Events 
Following initiation of study medication, collect all AEs, regardless of cause or relationship, 
until 12 weeks after last administration of study drug.  
All AEs should be followed up until resolution or until the AE is stable, if possible. Vir may 
request that certain AEs be followed beyond the protocol-defined follow-up period. 
Serious Adverse Events 
All SAEs, regardless of cause or relationship, that occur after the subject first consents to 
participate in the study (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol-required follow-up period, must be reported as instructed. This also 
includes any SAEs resulting from protocol-mandated procedures performed after informed 
consent is signed. 
Investigators are not obligated to actively seek SAEs after the protocol-defined follow-up period. 
However, if the investigator learns of any SAEs that occur after study participation has 
concluded and the event is deemed relevant to the use of study drug, he/she should promptly 
document and report the event to Vir.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 52 
27 MAR 2019 
•
For fatal or life-threatening events, copies of hospital case reports, discharge summaries,
autopsy reports, and other documents should be submitted by email or fax when
requested and applicable. Transmission of such documents should occur without personal
subject identification, maintaining the traceability of a document to the subject
identifiers.
•
Additional information may be requested to ensure the timely completion of accurate
safety reports.
•
Any medications necessary for treatment of the SAE must be recorded onto the
concomitant medication section of the subject’s eCRF and the event description section
of the SAE form.
•
Email or fax the SAE form within 24 hours of the investigator’s knowledge of the event.
Contact information is as follows:
8.4. 
Vir Reporting Requirements 
Depending on relevant local legislation or regulations, including the applicable US Food and 
Drug Administration Code of Federal Regulations, the EU Clinical Trials Directive 
(2001/20/EC) and relevant updates, and other country-specific legislation or regulations, the 
Sponsor may be required to expedite to worldwide regulatory agencies reports of SAEs, serious 
adverse drug reactions (SADRs), or SUSARs. In accordance with the EU Clinical Trials 
Directive (2001/20/EC), the Sponsor or a specified designee will notify worldwide regulatory 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
current regulations. 
Assessment of expectedness for SAEs will be determined by the Sponsor using reference safety 
information specified in the Investigator’s Brochure.  
All investigators will receive a safety letter notifying them of relevant SUSAR reports associated 
with any study drug. The investigator should notify the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required by local regulatory agencies, and in accordance with the local 
institutional policy. 
8.5. 
Special Situations Reports 
8.5.1. 
Definitions of Special Situations 
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy reports regardless of an 
associated AE. 
PPD


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 53 
27 MAR 2019 
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer. 
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a 
subject. 
Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information. 
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol (as it applies to the daily dose of the subject in question). In cases of a 
discrepancy in drug accountability, overdose will be established only when it is clear that the 
subject has taken the excess dose(s). Overdose cannot be established when the pharmacist cannot 
account for the discrepancy except in cases in which the investigator has reason to suspect that 
the additional dose(s) were administered to the subject. 
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
8.5.2. 
Instructions for Reporting Special Situations 
Pregnancy Reporting 
If a female subject becomes pregnant after the first study drug administration through the 
follow-up period (12 weeks after last study drug administration), the investigator must report the 
pregnancy to the Sponsor or designee within 24 hours of being notified of the pregnancy. The 
subject should receive any necessary counseling regarding the risk of continuing the pregnancy 
and the possible effects on the fetus.  
The pregnancy should be followed by the investigator until completion. At the completion of the 
pregnancy, the investigator will document the outcome of the pregnancy. If the outcome of the 
pregnancy results in a postpartum complication, spontaneous abortion, stillbirth, neonatal death 
or congenital anomaly, then the investigator should follow the procedures for reporting an SAE 
as outlined in Section 8.3.  
Reporting Other Special Situations 
All other special situations must be reported to 
 within 24 hours of the 
investigator becoming aware of the situation. These reports must consist of situations that 
involve study drug and/or protocol-required concomitant medications, but do not apply to 
non-required concomitant medications. Contact information is as follows: 
PPD
PPD


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 54 
27 MAR 2019 
Special situations involving non-required concomitant medications do not need to be reported; 
however, for special situations that result in AEs due to a non-required concomitant medication, 
the AE should be reported. 
Any inappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may be more appropriately documented as a protocol deviation. 
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time. Details of the symptoms and signs, clinical management, and outcome will be 
reported, when available. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 55 
27 MAR 2019 
9.
STATISTICAL CONSIDERATIONS
9.1. 
Objectives 
The objectives are listed in Section 2. 
9.2. 
Endpoints 
The endpoints are listed in Section 3. 
9.3. 
Analysis Conventions 
Descriptive statistics will be presented for continuous variables, and frequencies and percentages 
will be presented for categorical and ordinal variables. Percentages will be based on the number 
of nonmissing values in a dose group. 
9.3.1. 
Analysis Sets 
Safety 
The primary analysis set for safety analyses will be the Safety Analysis Set, which includes all 
subjects who received at least 1 dose of study drug. 
Pharmacokinetic 
The primary analysis set for PK analyses will be the PK Analysis Set, which includes all subjects 
in the Safety Analysis Set who have at least 1 nonmissing concentration data to provide 
interpretable results for the specific parameters of interest for the analyte under evaluation. 
Antiviral Activity 
The primary analysis set for antiviral activity analyses will be the Antiviral Analysis Set, which 
includes all subjects in the Safety Analysis Set who have at least 1 nonmissing data to provide 
interpretable results for the specific antiviral activity parameters of interest. 
9.3.2. 
Data Handling Conventions 
PK concentration values and PK parameter values below the limit of quantitation (BLQ) will be 
presented as “BLQ” in the data listings. BLQ values that occur prior to study drug administration 
will be treated as 0, BLQ values at all other timepoints will be treated as one-half of the lower 
limit of quantitation (LLOQ). 
Laboratory data that are continuous in nature but are less than the LLOQ or above the upper limit 
of quantitation will be imputed to the value of the lower or upper limit minus or plus 1 
significant digit, respectively (eg, if the result of a continuous laboratory test is < 30, a value of 
29 will be assigned; if the result of a continuous laboratory test is < 30.0, a value of 29.9 will be 
assigned). 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 56 
27 MAR 2019 
9.4. 
Demographic Data and Baseline Characteristics 
Demographic and baseline characteristics will be summarized using standard descriptive 
statistics including sample size, mean, standard deviation (SD), median, first quartile (Q1), third 
quartile (Q3), minimum, and maximum for continuous variables and numbers and of subjects for 
categorical variables. 
9.5. 
Safety Analysis 
All safety analyses will be performed using the Safety Analysis Set. Safety will be evaluated by 
assessment of clinical laboratory tests, physical examinations, ECGs, vital signs measurements at 
various timepoints during the study, and by the documentation of AEs. 
All safety data collected up to 12 weeks after the last study drug administration will be 
summarized by cohort for each VIR-2218 dose and placebo.  
9.5.1. 
Adverse Events 
Clinical and laboratory AEs will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA). System Organ Class (SOC), High-Level Group Term (HLGT), High-
Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be attached to the 
clinical database. 
Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs with an onset date of on 
or after the study drug start date and no later than 30 days after permanent discontinuation of 
study drug. 
Summaries (number and percentage of subjects) of TEAEs by SOC and PT will be provided by 
cohort. TEAEs will also be summarized by relationship to study drug and severity.  
9.5.2. 
Laboratory Evaluations 
Selected laboratory data will be summarized (n, mean, SD, median, Q1, Q3, minimum, and 
maximum) by cohort and study visit along with corresponding change from baseline. 
Graded laboratory abnormalities will be defined using CTCAE Version 5.0 grading scale. 
9.5.3. 
Other Safety Evaluations 
Individual data for physical examination findings, prior and concomitant medications and 
medical history will be provided. Twelve-lead ECGs and vital signs measurements will be listed 
by subject and summarized by incidence of events/abnormalities or descriptive statistics as 
appropriate. 
9.6. 
Pharmacokinetic/Pharmacodynamic Analysis 
PK parameters of VIR2218 and possible metabolites will be computed using standard 
noncompartmental methods. Parameters may include, but not be limited to, plasma: maximum 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 57 
27 MAR 2019 
concentration, time to reach maximum concentration, area under the concentration versus time 
curve (to the last measurable timepoint and to infinity), percent of area extrapolated, apparent 
terminal elimination half-life, clearance, and volume of distribution; urine: fraction eliminated in 
the urine and renal clearance, and will be listed and summarized using descriptive statistics. 
Other parameters may be calculated, if deemed necessary.  
PK/pharmacodynamic analyses will be conducted to explore exposure-response relationships 
between PK parameters and selected antiviral variables. These analyses may include graphical 
plots, tabular summaries, and various linear and/or nonlinear analyses. Details of the analysis 
will be provided in the Statistical Analysis Plan. 
9.7. 
Antiviral Activity Analysis 
For Part B/C, selected data relating to the antiviral activity of VIR2218, such as HBsAg, HBeAg, 
, anti-HBs, anti-HBe, 
, and HBV DNA levels, will be summarized (n, mean, 
SD, median, Q1, Q3, minimum, and maximum) by cohort and study visit along with 
corresponding change from baseline. Summaries (number and percentage of subjects) of HBsAg 
loss, anti-HBs seroconversion, HBeAg loss, and anti-HBe seroconversion will be provided by 
cohort and study visit. 
9.8. 
Sample Size 
No formal sample size calculation was conducted. Up to 104 subjects (up to 56 healthy subjects 
and up to 48 subjects with chronic HBV infection) are planned to complete the study. The 
104 subjects includes “floater” subjects (up to 8 healthy subjects and up to 16 subjects with 
chronic HBV infection) that may be added as part of expansion of an existing cohort or cohorts 
based on SRC recommendations if further data are necessary.  
CCI
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 58 
27 MAR 2019 
10.
RESPONSIBILITIES
10.1. 
Investigator and Sponsor Responsibilities 
10.1.1. 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC) 
Approval 
This protocol and any accompanying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study used to obtain informed 
consent) will be submitted by the investigator to an IRB or IEC. Approval from the IRB or IEC 
must be obtained before starting the study and should be documented in a letter to the 
investigator specifying the protocol number, protocol version, protocol date, documents 
reviewed, and date on which the committee met and granted the approval. 
Any modifications made to the protocol after receipt of IRB or IEC approval must also be 
submitted to the IRB or IEC for approval before implementation. 
10.1.2. 
Informed Consent 
The investigator will ensure that the subject is given full and adequate oral and written 
information about the nature, purpose, possible risk and benefit of the study. Subjects must also 
be notified that participation is completely voluntary and that they are free to discontinue from 
the study at any time. The subject should be given the opportunity to ask questions and allowed 
time to consider the information provided.  
The subject’s signed and dated informed consent must be obtained before conducting any study 
procedures.  
The investigator must maintain the original, signed Informed Consent Form (ICF). A copy of the 
signed ICF must be given to the subject. 
10.1.3. 
Confidentiality 
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only subject initials and date of birth (where 
local regulations allow) and an identification code (ie, not names) should be recorded on any 
form or biological sample submitted to the Sponsor, IRB or IEC, or laboratory. The investigator 
must keep a screening log showing codes, names, and addresses for all subjects screened and for 
all subjects enrolled in the trial. 
The investigator agrees that all information received from the Sponsor, including but not limited 
to the Investigator’s Brochure, this protocol, CRFs, the investigational new drug, and any other 
study information, remain the sole and exclusive property of the Sponsor during the conduct of 
the study and thereafter. This information is not to be disclosed to any third party (except 
employees or agents directly involved in the conduct of the study or as required by law) without 
prior written consent from the Sponsor. The investigator further agrees to take all reasonable 
precautions to prevent the disclosure by any employee or agent of the clinical investigative site 
to any third party or otherwise into the public domain. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 59 
27 MAR 2019 
In compliance with local and/or regional regulations, this clinical study may be registered and 
study results may be posted on public registries, such as ClinicalTrials.gov.  
10.1.4. 
Study Files and Retention of Records 
All documentation relating to the study should be retained for the period of time required by 
applicable local law. If it becomes necessary for the Sponsor or designee, applicable IRB/IEC, or 
applicable regulatory authorities to review or audit any documentation relating to the study, the 
investigator must permit direct access to all source documents/data. Records will not be 
destroyed without informing the Sponsor in writing and giving the Sponsor the opportunity to 
store the records for a longer period of time at the Sponsor’s expense.  
10.1.5. 
Electronic Case Report Forms (eCRF) 
Study data must be recorded on electronic CRFs (eCRFs) provided by the Sponsor or designee 
on behalf of the Sponsor. eCRFs must be completed only by the investigator or person 
designated by the investigator. eCRF data must be entered by trained clinical investigative site 
personnel with access to a valid and secure eCRF system. All data entered into the eCRF must 
also be available in the source documents. Correction on source documents must be made so as 
to not obliterate the original data and must be initialed and dated by the person who made the 
correction.  
10.1.6. 
Good Clinical Practice 
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the guidelines of Good Clinical Practice (GCP). Compliance with 
GCP provides public assurance that the rights, safety, and well-being of study subjects are 
protected consistent with the principles that have their origin in the Declaration of Helsinki 
(revised version of Edinburgh, Scotland, 2000), International Conference on Harmonisation 
(ICH) guidelines, or with the laws and regulations of the country in which the research is 
conducted, whichever affords the greater protection to the study subject.  
10.1.7. 
Drug Accountability 
The investigator or designee (ie, pharmacist) is responsible for ensuring adequate accountability 
of all used and unused investigational product and placebo. Refer to the Pharmacy Manual for 
further information.  
10.1.8. 
Quality Control and Assurance 
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core trial process and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reports according to the 
protocol, GCP guidelines of ICH, an any applicable regulatory requirements. A regulatory 
authority, an IEC or an IRB may visit the clinical investigative site to perform audits or 
inspections, including source data verification. The investigator should contact the Sponsor, or 
its designee, immediately if contact by a regulatory agency about an inspection.  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 60 
27 MAR 2019 
10.1.9. 
Protocol Compliance 
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol. 
10.1.10. 
Protocol Modifications 
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by the Sponsor. All protocol modifications must be submitted to the IRB or IEC in 
accordance with local requirements. Approval must be obtained before changes can be 
implemented. 
10.1.11. 
Study Report and Publications 
A clinical study report will be prepared and provided to the regulatory agency(ies). 
The Sponsor will ensure that the report meets the standards set out in the ICH Guideline for 
Structure and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may 
be prepared in certain cases. 
After conclusion of the study and without prior written approval from the Sponsor, investigators 
in this study may communicate, orally present, or publish in scientific journals or other scholarly 
media only after the following conditions have been met: 
•
the results of the study in their entirety have been publicly disclosed by or with the
consent of the Sponsor in an abstract, manuscript, or presentation form; or
•
the study has been completed at all clinical investigative sites for at least 2 years
No such communication, presentation, or publication will include the Sponsor’s confidential 
information (Section 10.1.3). 
The investigator will submit any proposed publication or presentation along with the respective 
scientific journal or presentation forum at least 30 days before submission of the publication or 
presentation. The investigator will comply with the Sponsor’s request to delete references to its 
confidential information (other than the study results) in any paper or presentation and agrees to 
withhold publication or presentation for an additional 60 days to obtain patent protection if 
deemed necessary. 
10.2. 
Study Monitoring 
In accordance with ICH GCP guidelines, the study monitor must have access to the 
investigator’s source documentation to verify the data recorded in the CRFs for consistency. 
The monitor is responsible for routine review of the CRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to any subject records needed to 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 61 
27 MAR 2019 
verify the entries on the CRFs. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected during these monitoring visits are resolved.  
10.2.1. 
Study Discontinuation 
The Sponsor reserves the right to terminate the overall study at any time. The investigator 
reserves the right to discontinue the study at their institution at any time. Should this be 
necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies), IRBs, and IECs. In terminating the study, the Sponsor and the 
investigator will assure that adequate consideration is given to the protection of the subjects’ 
interests. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 62 
27 MAR 2019 
11.
REFERENCES
1. Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017;9: 156. doi:
10.3390/v9060156
2. Burton AR, Pallett LJ, McCoy L, Suveizdyte K, Amin OE, Froghi F, Davidson BR, Gill US,
Kennedy PTF, Blair PA, Mauri C, Pelletier N, and Maini MK Dysfunctional surface antigen-
specific memory B cells accumulate in chronic hepatitis B infection. EASL International
Liver Congress, Paris, France 2018
3. Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. Journal of Hepatology. 2016;
64(1): S71 - S83. doi: 10.1016/j.jhep.2016.01.026
4. Hepatitis B Fact sheet. World Health Organization Website. http://www.who.int/mediacentre
/factsheets/fs204/en/. Updated July 2017.
5. Konerman MA, Lok AS. Interferon Treatment for Hepatitis B.Clinics in Liver Disease.
2016;20(4): 645-665. doi: 10.1016/j.cld.2016.06.002
6. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma.
Journal of Hepatology. 2016;64(1): S84 - S101. doi: 10.1016/j.jhep.2016.02.021
7. Li Y, Si L, Zhai Y, et al. Genome-wide association study identifies 8p21.3 associated with
persistent hepatitis B virus infection among Chinese. Nature Communications. 2016;7:11664.
doi:10.1038/ncomms11664.
8. Liang TJ, Block TM, McMahon BJ, et al. Present and Future Therapies of Hepatitis B: From
Discovery to Cure. Hepatology. 2015;62(6):1893-1908. doi:10.1002/hep.28025.
9. Lucifora J, Protzer U. Attacking hepatis B virus cccDNA—The holy grail to hepatitis B cure.
Journal of Hepatology. 2016;64(1): S41-S48. doi: 10.1016/j.jhep.2016.02.009
10. Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment
of HBV infection. Journal of Hepatology. 2016;64(1): S60-S70. 10.1016/j.jhep.2016.01.028
11. Protzer U, Maini MK, Knoelle PA. Living in the liver: hepatic infections. Nature Reviews
Immunology. 2012;12: 201-213. doi:10.1038/nri3169
12. Schweitzer A, Horn J, Mikolajczyk RT, Kraus G, Ott JJ. Estimations of worldwide
prevalence of chronic hepatitis B virus infection: a systematic review of data published
between 1965 and 2013. The Lancet. 2015;387(10003):1546-1555. doi: 10.1016/S0140-
6736(15)61412-X
13. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015; 479-
480:672-686. doi: 10.1016/j.virol.2015.02.031.


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 63 
27 MAR 2019 
14. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990
to 2013: findings from the Global Burden of Disease Study 2013. Lancet (London, England).
2016;388(10049):1081-1088. doi:10.1016/S0140-6736(16)30579-7.
15. Tong S, Revill P. Overview of viral replication and genetic variability. Journal of
hepatology. 2016;64(1):S4-S16. doi:10.1016/j.jhep.2016.01.027.
16. Trepo C. A brief history of hepatitis milestones. Liver International. 2014;34(1):29-37.doi:
10.1111/liv.12409


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 64 
27 MAR 2019 
12.
APPENDICES
Appendix 1. 
Investigator Signature Page 
Appendix 2. 
Part A Schedule of Study Assessments for SAD Cohorts in Healthy Adult 
Subjects 
Appendix 3. 
Part B/C Schedule of Study Assessments for MAD Cohorts in Subjects 
with Chronic HBV Infection 
Appendix 4. 
Part A Pharmacokinetic Assessment Timepoints 
Appendix 5. 
Part B/C Pharmacokinetic Assessment Timepoints 
Appendix 6. 
Cohort Dosing Schedule 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 65 
27 MAR 2019 
Appendix 1. Investigator Signature Page 
VIR BIOTECHNOLOGY, INC  
499 ILLINOIS STREET SUITE 500 
SAN FRANCISCO, CA 94158 
STUDY ACKNOWLEDGMENT 
 A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, 
Pharmacokinetics, and Antiviral Activity of VIR-2218 
VIR-2218-1001, Protocol Amendment 2, 27 March 2019 
This protocol has been approved by Vir Biotechnology, Inc. The following signature documents this 
approval.  
Vir Study Director and Medical Monitor 
{See Appended Electronic Signature Page} 
Printed Name 
Signature and Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary details for 
me and my staff to conduct this study as described. I will conduct this study as outlined herein and will 
make a reasonable effort to complete the study within the time designated.  
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Vir Biotechnology, Inc. I will discuss this material with them to ensure they 
are fully informed about the drugs and the study.  
Principal Investigator Printed Name 
Signature 
Date 
PPD


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 66 
27 MAR 2019 
Appendix 2. Part A Schedule of Study Assessments for SAD Cohorts in Healthy Adult Subjects 
Part A 
Study Stage 
Inpatienta 
Outpatient 
(Post-dose Follow-up Period) 
Screening 
Study Visit Week 
W1 
W2 
W3 
W4 
W8 
W12 
Study Visit Day±Visit Window 
D −28 to −2 
D −1 
D1b 
D2 
D3 
D8±2 
D15±2 
D22±2 
D29±2 
D57±7 D85±7/ET 
Informed consent 
X 
Demography 
X 
Medical history
c 
X 
Inclusion/exclusion criteria 
X 
X
d 
Full physical examination
e 
X 
X 
Symptom-directed physical 
examination 
X 
X 
X 
X 
X 
X 
X 
X 
Alcohol assessment
f 
X 
X 
X 
X 
X 
X 
X 
Body weight 
X 
Height and BMI 
X 
Vital signs
g 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety ECGsh 
X 
X 
X 
X 
Cardiodynamic ECG evaluation
i 
X 
X 
Pregnancy test
j 
X 
X 
X 
X 
X 
Screening viral serology
k 
X 
Laboratory assessments
l 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysisl 
X 
X 
X 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 67 
27 MAR 2019 
Part A 
Study Stage 
Inpatienta 
Outpatient 
(Post-dose Follow-up Period) 
Screening 
Study Visit Week 
W1 
W2 
W3 
W4 
W8 
W12 
Study Visit Day±Visit Window 
D −28 to −2 
D −1 
D1b 
D2 
D3 
D8±2 
D15±2 
D22±2 
D29±2 
D57±7 D85±7/ET 
Urine for drugs of abuse
m 
X 
X 
Randomization 
X 
Study drug administrationn 
X 
Blood samples for PK analysiso 
X 
X 
X 
X 
Urine samples for PK analysiso 
X 
X 
X 
Pooled urineo 
X 
X 
Review/record AEsp 
X 
Concomitant medications 
X 
AE = adverse event; BMI = body mass index; ECG = electrocardiogram; ET = End of Treatment; PK = pharmacokinetic; SAD = single ascending dose 
Note: When scheduled at the same timepoints, the assessments of vital signs and 12-lead ECGs must be performed first, before the physical examinations, blood 
sample collections, and urine collections. 
a Subjects will be admitted to the clinical investigative site on Day −1 and discharged following the completion of the Day 2 assessments. If a subject 
discontinues prematurely, ET assessments should be performed. 
b Assessments performed predose unless otherwise specified. 
c Complete medical history will be taken at screening and any changes should be updated prior to dosing. 
d Evaluation of inclusion criteria related to urine pregnancy testing and urine drug screen. 
e See Section 7.2.1 for assessments to be performed during a full physical examination. 
f Subjects’ alcohol intake will be recorded while on study. 
g Vital signs (blood pressure, pulse rate, respiratory rate and temperature) should be measured after the subject has rested comfortably for approximately 10 
minutes. On Day 1, vital signs should be measured within 2 hours predose and 4 hours post-dose. On all other visit days, vital signs are only required to be 
recorded once during the visit.  
h 12-lead safety ECGs will be recorded on the timepoints listed in Appendix 4 and should be measured in the supine position after the subject has rested 
comfortably for 10 minutes. 
i Replicate 12-lead ECGs will be extracted at the central ECG laboratory at timepoints shown in Appendix 4. Subjects must be resting supine for at least 10 
minutes prior to and 5 minutes after each nominal timepoint.  
j WOCBP are required to have pregnancy tests. A blood pregnancy test will be performed at screening and urine pregnancy tests will be performed thereafter. 
Negative pregnancy test must be confirmed prior to study drug administration. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 68 
27 MAR 2019 
k See Section 7.1.3 for viral serology parameters. 
l Clinical laboratory and urinalysis parameters are described in Section 7.2.8.
m Drugs of abuse included in the screen are described in the inclusion/exclusion criteria. Screening results for drugs of abuse must be reviewed prior to dosing.
n Study drug will be administered via SC injection as described in Section 6.2.4.
o Blood and urine samples for PK analysis will be collected at the timepoints listed in Appendix 4.
p All AEs related to screening activities must be collected from the time of consent onwards; any other events occurring during the screening period should be
reported as medical history. All SAEs must be collected from the time of consent onwards. 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 69 
27 MAR 2019 
Appendix 3.  Part B/C Schedule of Study Assessments for MAD Cohorts in Subjects with Chronic HBV Infection 
Part B/C 
Study Stage 
Screening 
Dosing Period 
Post-dose Follow-up Periodb 
Extended Follow-up 
Periodc 
Study Visit Week 
W1 
W2 
W3 
W4a 
W5 
W6 
W7 
W8 
W12 
W16 W20 
W24 
Study Visit Day 
±Visit Window 
D −28 to −1 D1a 
D2 
D8 
±2 
D15 
±2 
D22 
±2 
D29a 
±2 
D36 
±2 
D43 
±2 
D50 
±2 
D57 
±2 
D85 
±7 
D113 
±7/ET 
D141
±7 
D169 
±7 
Q28D 
±7 
Informed consent 
X 
Demography 
X 
Medical history including 
HBV genotyped 
X 
Inclusion/exclusion 
criteria 
X 
X
e 
Full physical examinationf 
X 
X 
X 
Symptom-directed 
physical examination 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Alcohol intake 
assessmentg 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Body weight 
X 
Height and BMI 
X 
Vital signsh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety ECGi 
X 
X 
X 
X 
Pregnancy testj 
X 
X 
X 
X 
X 
X 
FibroScank 
X 
Screening viral serologyl 
X 
Laboratory assessmentsm  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xn 
Xn 
Xn 
Urinalysism 
X 
X 


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 70 
27 MAR 2019 
Part B/C 
Study Stage 
Screening 
Dosing Period 
Post-dose Follow-up Periodb 
Extended Follow-up 
Periodc 
Study Visit Week 
W1 
W2 
W3 
W4a 
W5 
W6 
W7 
W8 
W12 
W16 W20 
W24 
Study Visit Day 
±Visit Window 
D −28 to −1 D1a 
D2 
D8 
±2 
D15 
±2 
D22 
±2 
D29a 
±2 
D36 
±2 
D43 
±2 
D50 
±2 
D57 
±2 
D85 
±7 
D113 
±7/ET 
D141
±7 
D169 
±7 
Q28D 
±7 
Urine for drugs of abuseo 
X 
Randomization 
X 
Study drug 
administrationp 
X 
X 
Blood samples for PK 
analysisq 
X 
X 
X 
Xr 
X 
Blood sample for HBsAg 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood sample for anti-
HBs 
X 
X 
X 
X 
Xs 
Blood sample for HBeAg 
qualitative 
X 
Blood sample for HBeAg 
quantitative for Part C 
onlyt
X 
X 
X 
X 
X 
X 
Xs 
Blood sample for anti-
HBe for Part C only 
X 
X 
X 
X 
Xs 
Blood sample for HBV 
DNA quantitationu 
X 
X 
X 
X 
X 
X 
X 
X 
Xs 
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 71 
27 MAR 2019 
Part B/C 
Study Stage 
Screening 
Dosing Period 
Post-dose Follow-up Periodb 
Extended Follow-up 
Periodc 
Study Visit Week 
W1 
W2 
W3 
W4a 
W5 
W6 
W7 
W8 
W12 
W16 W20 
W24 
Study Visit Day 
±Visit Window 
D −28 to −1 D1a 
D2 
D8 
±2 
D15 
±2 
D22 
±2 
D29a 
±2 
D36 
±2 
D43 
±2 
D50 
±2 
D57 
±2 
D85 
±7 
D113 
±7/ET 
D141
±7 
D169 
±7 
Q28D 
±7 
Review/Record AEsx 
X 
Concomitant Medications 
X 
NUC medication 
adherence 
X 
AE = adverse event; ECG = electrocardiogram; ET=end of treatment; 
 
n
 HBeAg = hepatitis e-antigen; HBsAg = 
hepatitis B surface antigen; HBV = Hepatitis B Virus; NUC = nucleoside/nucleotide; PK = pharmacokinetics; MAD = multiple ascending dose 
Note: When scheduled at the same timepoints, the assessments of vital signs and 12-lead ECGs must be performed first, before the physical examinations, 
blood sample collections, and urine collections. 
a Assessments performed predose unless otherwise specified. 
b If a subject withdraws prematurely from the study prior to their Week 16 visit, ET assessments should be performed. 
c Additional HBsAg monitoring is required for subjects with HBsAg levels with a > 10% decrease from the Day 1 predose level at the Week 16 visit. Visits will 
occur every 4 weeks starting at Week 20 up to Week 48 or until the HBsAg level returns to > 90% of the Day 1 predose level. For example, if Day 1 predose 
HBsAg is 560 IU/mL and Week 16 HBsAg is 490 IU/mL, the subject will be followed until HBsAg levels returns to ≥ 504 IU/mL. Additional HBsAg 
monitoring may be discontinued at the Sponsor’s discretion based on emerging data.  
d A complete medical history will be taken at screening including HBV genotype if available. Any changes should be updated prior to dosing. 
e Evaluation of inclusion criteria related to urine pregnancy testing and urine drug screen. 
f See Section 7.2.1 for assessments to be performed during a full physical examination. 
g Subjects’ alcohol intake will be recorded while on study. 
h Vital signs (blood pressure, pulse rate, respiratory rate, and temperature) should be measured in the supine position after the subject has rested comfortably for 
approximately 10 minutes. On Day 1, vital signs should be measured within 2 hours predose and 4 hours post-dose. On all other visit days, vital signs are 
only required to be recorded once during the visit. 
i 12-lead safety ECGs will be recorded on the timepoints listed in Appendix 5 and should be measured in the supine position after the subject has rested 
comfortably for 10 minutes. 
j WOCBP are required to have pregnancy tests. A serum pregnancy test will be performed at screening and urine pregnancy tests will be performed thereafter. 
Negative pregnancy test must be confirmed prior to study drug administration. 
k Does not need to be performed if the subject has had a FibroScan in the 6 months prior to screening or liver biopsy in the year prior to screening that confirmed 
the absence of Metavir F3 fibrosis or F4 cirrhosis. 
l See Section 7.1.3 for viral serology parameters.
CCI
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 72 
27 MAR 2019 
m Clinical laboratory and urinalysis parameters are described in Section 7.2.8. 
n Liver function tests only. 
o Drugs of abuse included in the screen are described in the inclusion/exclusion criteria. Screening results for drugs of abuse must be reviewed prior to dosing.
p Study drug will be administered via SC injection as described in Section 6.2.4.
q Blood samples for PK analysis will be collected at the timepoints listed in Appendix 5.
r As a part of the Week 4 visit, subjects will return to the study center 24-hours after their initial post dose Week 4 PK sample is drawn to have a 24-hour post
dose PK sample drawn. 
s Testing should occur again only at Week 36 and Week 48. 
e
i
e
u
u
e
u If a subject experiences ALT flare (as defined by ALT > 2x ULN) additional HBV DNA quantitation sample(s) may be collected
o
x Al AEs related to screening activities must be collected from the time of consent onwards; any other events occurring during the screening period should be 
reported as medical history. All SAEs must be collected from the time of consent onwards.
CCI
CCI
CCI


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 73 
27 MAR 2019 
Appendix 4.  Part A Pharmacokinetic Assessment Timepoints 
Study Day/Week 
Protocol 
Time 
PK Blood 
Urine PK 
Pooled 
Urine 
Cardiodynamic 
Extracted ECGs 
Safety 
ECGs 
Screening 
 
 
 
 
 
X 
Day 1 
Predose  
Xa 
Xa 
 
Xb 
X 
Dose 
 
 
X  
0-4 hours 
 
 
30 min 
X 
 
X 
  
1 hour 
X 
 
X 
X 
2 hours 
X 
 
X 
 
4 hours 
X 
 
X  
4-8 hours 
X 
 X 
6 hours 
X 
 
X 
  
8 hours 
X 
 
X  
8-12 hours 
X 
X 
10 hours 
X 
 
X 
  
12 hours 
X 
 
X  
12-24 
hours 
X 
  
Day 2 
24 hours 
X 
 
X 
X  
Day 3 
48 hours 
X 
X 
 
 
  
Week 1 
 
X 
X 
 
 
 X 
a  At ≤ 15 minutes prior to dosing  
b At 3 timepoints (-45, -30 and -15 minutes) prior to dosing  


VIR-2218-1001 
Clinical Study Protocol 
Final 
 
CONFIDENTIAL 
Page 74 
27 MAR 2019 
Appendix 5. Part B/C Pharmacokinetic Assessment Timepoints 
Study Day/Week 
Protocol Time  
PK Blood 
 Safety ECGs 
Screening 
 
 
X 
Day 1 
Predose  
Xa 
X 
Dose 
 
 
1 hour 
X 
 
2 hours 
X 
 
4 hours 
X 
X 
8 hours 
X 
X 
Day 2 
24 hours 
X 
 X 
Week 1 
 
X 
  
Week 4 
Predose  
Xa 
X 
 
Dose 
 
 
 
1 hour 
X 
 
 
2 hours 
X 
 
 
4 hours 
X 
X 
 
8 hours 
X 
 
 
24 hours 
X 
 
Week 5 
 
X 
  
a At ≤ 15 minutes prior to dosing  


VIR-2218-1001 
Clinical Study Protocol 
Final 
CONFIDENTIAL 
Page 75 
27 MAR 2019 
Appendix 6. Cohort Dosing Schedule 
 
 

SAP_001.pdf: 
Official Title: A Phase 1/2, Randomized, Placebo-Controlled 
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, 
and Antiviral Activity of VIR-2218 
NCT Number: NCT03672188 
Document Date: Statistical Analysis Plan, 22 December 2020 


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 1 of 41 
STATISTICAL ANALYSIS PLAN 
PROTOCOL NO.: 
VIR-2218-1001 
PRODUCT CODE: 
VIR-2218 
PREPARED FOR: 
Vir Biotechnology, Inc. 
499 Illinois Street 
Suite 500 
San Francisco 
CA 94158 
USA 
DATE OF ISSUE: 
22 December 2020 
VERSION/STATUS: 
Version 2.3 
VERSION HISTORY: Version 2.2 (6 November 2020) 
Version 2.1 (1 October 2020) 
Version 2.0 (25 August 2020) 
Version 1.0 (09 October 2019) 
Version 0.95 (07 October 2019) 
Version 0.9 (13 September 2019) 
Version 0.2 (20 August 2019) 
AUTHOR: 
PPD
PPD
PPD
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 2 of 41 
SAP APPROVAL 
By my signature, I confirm that this SAP has been reviewed by Vir Biotechnology, Inc. and 
has been approved for use for the VIR-2218-1001 study: 
Name 
Title / Company 
Signature/Date 
Director, Statistics 
Principal Biostatistician 
PPD
PPD
PPD
PPD
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 3 of 41 
Table of contents 
1.
INTRODUCTION
7 
2.
PROJECT OVERVIEW
8 
2.1 
Study Design 
8 
2.2 
Objectives 
11 
2.3 
Endpoints 
11 
2.4 
Sample Size 
13 
2.5 
Randomization 
13 
3.
STATISTICAL CONSIDERATIONS
15 
3.1 
General Considerations 
15 
3.2 
Key Definitions 
16 
3.3 
Hypothesis Testing and Inferential Analyses 
17 
3.4 
Multiple Comparisons and Multiplicity Adjustments. 
17 
3.5 
Coding of Events and Medications 
17 
3.6 
Cohorts (Treatment Groups) 
17 
4.
ANALYSIS SETS
19 
4.1 
Analysis Set Descriptions 
19 
5.
SUBJECT DISPOSITION AND ANALYSIS SETS
20 
6.
PROTOCOL DEVIATIONS
21 
7.
DEMOGRAPHIC AND BASELINE INFORMATION
22 
7.1 
Demographics 
22 
7.2 
Viral Serology 
22 
7.3 
Medical History 
22 
7.4 
Urine Drug Test 
22 
7.5 
Cirrhosis Status 
22 
8.
TREATMENT EXPOSURE
23 
9.
PHARMACOKINETICS (PK)
24 
9.1 
9.3 CONCENTRATION-TIME PROFILES 
25 
9.2 
Plasma PK Parameters 
25 
9.5 
Urine PK Parameters 
28 
9.6 
DOSE PROPORTIONALITY FOR PK PARAMETERS 
28 
10.
PHARMACODYNAMICS (PD)
28 
11.
EFFICACY
28 
12.
SAFETY
29 
12.1 Adverse Events 
29 
12.2 Safety Laboratory Assessments 
29 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 4 of 41 
12.3 Vital Signs Measurements 
31 
12.4 12-Lead Safety Electrocardiogram (ECG)
32 
12.5 Physical Examinations 
32 
12.6 Substance Use 
32 
12.7 Pregnancy Test Results 
33 
12.8 Concomitant Medications 
33 
13.
ANTIVIRAL ACTIVITY
34 
13.1 Definition of variables 
34 
13.2 Biostatistical methods 
34 
14.
HANDLING OF MISSING DATA
35 
15.
CHANGES TO THE PLANNED ANALYSIS
36 
16.
INTERIM AND FINAL ANALYSIS
37 
16.1 Interim Analysis 1 
37 
16.2 Final Analysis (End of Study) 
38 
17.
SOFTWARE
39 
18.
TABLES, Listings and figures
40 
19.
REFERENCES
41 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 5 of 41 
List of Abbreviations 
Abbreviation 
Description 
AE 
Adverse Event 
ALP 
Alkaline Phosphatase 
ALT 
Alanine Aminotransferase 
Anti-HBe 
Hepatitis B extracellular antibody 
AST 
Aspartate Aminotransferase 
ATC 
Anatomical Therapeutic Chemical 
BMI 
Body Mass Index 
BUN 
Blood urea nitrogen 
cccDNA 
Covalently Closed Circular DNA 
C-G
Cockroft-Gault 
CHB 
Chronic Hepatitis B 
CS 
Clinically Significant 
CSR 
Clinical Study Report 
CV 
Coefficient of Variation 
DBP 
Diastolic Blood Pressure 
ECG 
Electrocardiogram 
eCRF 
Electronic Case Report Form 
FU 
Follow-up 
GCP 
Good Clinical Practice 
GGT 
Gamma-Glutamyl Transferase 
HBV 
Hepatitis B Virus 
HBeAg 
Hepatitis B e-Antigen 
HBsAg 
Hepatitis B Surface Antigen 
HCV 
Hepatitis C Virus 
HIV 
Human Immunodeficiency Virus 
INR 
International Normalized Ratio 
IVRS/IWRS 
Interactive Voice/Web Response System 
LDH 
Lactic Acid Dehydrogenase 
LLOQ 
Lower limit of quantification 
LOD 
Limit of Detection 
MAD 
Multiple Ascending Dose 
MedDRA 
Medical Dictionary for Regulatory Activities 
N/A 
Not Applicable 
NCS 
Not Clinically Significant 
NK 
Not Known 
NRTI 
Nucleos(t)ide Reverse Transcriptase Inhibitor 
PD 
Pharmacodynamic 
PI 
Principal Investigator 
PK 
Pharmacokinetic 
CCI
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 6 of 41 
Abbreviation 
Description 
PT 
Preferred Term 
Q1 
First Quartile 
Q3 
Third Quartile 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SAD 
Single Ascending Dose 
SBP 
Systolic Blood Pressure 
SD 
Standard Deviation 
S.I.
International System of Units 
SRC 
Safety Review Committee 
SOC 
System Organ Class 
SOP 
Standard Operating Procedure 
SUSAR 
Suspected Unexpected Serious Adverse Reactions 
TEAE 
Treatment Emergent Adverse Event 
TSH 
Thyroid Stimulating Hormone 
ULOQ 
Upper limit of quantification 
WHO-DD 
World Health Organization Drug Dictionary 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 7 of 41 
1.
INTRODUCTION
The following Statistical Analysis Plan (SAP) provides the outline for the statistical analysis of 
the data collected from the VIR-2218-1001 study 
The planned analyses identified in this SAP may be included in clinical study reports (CSRs), 
regulatory submissions, or future manuscripts. Also, post hoc exploratory analyses not 
necessarily identified in this SAP may be performed to further examine study data. Any post 
hoc, or unplanned, exploratory analyses performed will be clearly identified as such in the final 
CSR. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 8 of 41 
2.
PROJECT OVERVIEW
2.1 
Study Design 
Part A to C: 
This is a randomized, double-blind, placebo-controlled study of VIR-2218 administered 
subcutaneously to healthy adult subjects and non-cirrhotic adult subjects with chronic hepatitis 
B virus (HBV) infection who are on nucleos(t)ide reverse transcriptase inhibitor (NRTI) therapy. 
The study is designed to evaluate the safety, tolerability, Pharmacokinetic (PK), and antiviral 
activity of VIR-2218. Part A is planned to be conducted at 1 clinical investigative site; Parts B 
and C are planned to be conducted at multiple clinical investigative sites in the Asia-Pacific 
region. The study designs for Part A, phase 1 single ascending dose (SAD) and Part B/C, 
phase 2 multiple ascending dose (MAD) are presented in Figure 1 and Figure 2, respectively. 
Figure 1: SAD Study Design for Part A 
aSubject discharge will occur after all assessments are completed on Day 2. 
Figure 2: MAD Study Design for Part B/C 
aAdditional Hepatitis B Surface Antigen (HBsAg) monitoring is required for subjects with HBsAg levels with a > 
10% decrease from the Day 1 predose level at the Week 16 visit. Visits will occur every 4 weeks starting at Week 
20 up to Week 48 or until the HBsAg level returns to > 90% of the Day 1 predose level. Additional HBsAg 
monitoring may be discontinued at the Sponsor’s discretion based on emerging data. 
Part A Single Ascending Dose Phase in Healthy Adult Subjects 
Healthy adult subjects will be enrolled in 1 of 4 planned ascending dose cohorts. At the start 
of each cohort, 2 sentinel subjects will be randomized 1:1 to VIR 2218 or placebo. These 
subjects will be dosed concurrently and monitored for 24 hours; if the investigator has no safety 
concerns, the remainder of the subjects in the same cohort will be dosed. Vital signs, symptom-
directed physical examination(s), and AEs will be reviewed by the investigator prior to dosing 
any additional subjects. The remaining subjects will be randomized 5:1 to receive a single dose 
of VIR 2218 or placebo. 
Subject screening will occur no more than 4 weeks prior to the Day 1 visit. Eligible subjects will 
be confined to the clinical investigative site on Day −1 to determine continued eligibility and for 
predose assessments. Subjects in each cohort will be randomized to receive VIR- 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 9 of 41 
2218 or placebo within 48 hours prior to study drug administration. Subjects will receive a single 
dose of study drug on Day 1 (VIR 2218 or placebo). Subjects will be discharged from the clinical 
investigative site after all assessments are completed on Day 2. 
Subjects will return to the clinical investigative site on an outpatient basis for safety, tolerability, 
and PK monitoring at specified timepoints through the last Post-dose Follow-up Visit (Week 
12). 
Based on review of the accumulated, available data in Part A, the SRC may recommend dosing 
of 2 optional cohorts. In addition to the optional cohorts, up to 8 “floater” subjects for Part A 
may be added to any cohort, as determined and approved by the SRC. 
Fasting is not required for any study procedure/assessment. 
Part B/C Multiple Ascending Dose Phase in Non-Cirrhotic Adult Subjects with Chronic HBV 
Infection on Nucleoside/Nucleotide Therapy 
Non-cirrhotic adult subjects with chronic HBV infection on NRTI therapy for ≥ 6 months will be 
enrolled in the Part B/C cohorts. Part B will enroll HBeAg negative subjects. Part C will enroll 
HBeAg positive subjects. Eligible subjects should have HBV DNA < 90 IU/mL. Each cohort in 
Part B/C will be composed of 4 subjects randomized 3:1 to VIR 2218 or placebo, respectively. 
There are 3 planned and 2 optional cohorts in Part B. There are 1 planned and 2 optional 
cohorts in Part C. 
Subjects enrolled in Part B/C of the study will remain outpatient. Subject screening will occur 
no more than 4 weeks prior to the Day 1 visit. Eligible subjects will undergo further assessments 
on Day 1 to qualify for study drug administration on Day 1. To exclude the presence of cirrhosis, 
screening will include a mandatory noninvasive assessment of liver fibrosis such as a 
FibroScan evaluation, unless the subject has results from a FibroScan evaluation performed 
within 6 months prior to screening or a liver biopsy performed within 1 year prior to screening 
that confirms the absence of Metavir F3 fibrosis or F4 cirrhosis. 
Subjects in each cohort will be randomized 3:1 to receive VIR 2218 or placebo within 48 
hours prior to study drug administration on Day 1. Subjects will return to the clinical investigative 
site at Week 4 to receive a second dose of the same study drug administered on Day 1. The 
decision to administer a second dose will be made based on Week 3 laboratory values in 
accordance with dose suspension/stopping criteria in Section 4.84.6. 
Additional blood samples for possible analyses to elucidate VIR 2218 activity and/or host 
responses to infection and treatment will be collected. 
Subjects will return to the clinical investigative site on an outpatient basis for safety, tolerability, 
PK, and antiviral activity monitoring at specified timepoints through the last Post dose Follow 
up Visit (Week 16). Additional HBsAg monitoring is required for subjects with HBsAg levels with 
a > 10% decrease from the Day 1 predose level at the Week 16 visit. Visits will occur every 4 
weeks starting at Week 20 up to Week 48 or until the HBsAg level returns to > 90% of the Day 
1 predose level. Additional HBsAg monitoring may be discontinued at the Sponsor’s discretion 
based on emerging data. 
Based on review of the accumulated, available data in Parts A, B, and C, the SRC may 
recommend dosing of optional cohorts following the same stratification. In addition to the 
optional cohorts, a combined total of up to 16 “floater” subjects for Part B/C may be added to 
any cohort, as determined and approved by the SRC. 
Fasting is not required for any study procedure/assessment. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 10 of 41 
Safety Review Committee 
In Parts A – C, a SRC will perform ongoing reviews of safety, tolerability, and available study 
data collected throughout the study with the primary purpose of protecting the safety of subjects 
participating in this clinical study. The SRC will be governed by an SRC Charter that will be 
finalized prior to screening the first subject. 
The SRC will undertake safety data review prior to initiation of dosing a new cohort in Parts A, 
B, and C of the study in accordance with the SRC Charter. Ad hoc SRC meetings may take 
place as needed, e.g., for a significant safety event such as a subject or cohort stopping 
criterion being reached (Section 4.8 of the protocol). In Parts D - F of the study, the SRC may 
meet ad hoc, and/or in the event an unexpected safety concern is identified. 
Decisions to suspend dosing or discontinue individual subjects from study drug will be made 
according to predetermined stopping rules (Section 4.8 of the protocol). Additionally, the SRC 
may recommend discontinuation of the study to the Sponsor. The SRC membership 
composition is described in detail in the SRC Charter. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 11 of 41 
2.2 
Objectives 
2.2.1 Primary objective 
The primary objectives of this study are: 
•
Part A: To evaluate the safety and tolerability of a single dose of VIR-2218 in healthy
adult subjects.
•
Part B/C: To evaluate the safety and tolerability of multiple doses of VIR-2218 in non- 
cirrhotic subjects with HBeAg-negative (Part B) and HBeAg-positive (Part C) chronic HBV
infection on NRTI therapy.
2.2.2 Secondary objectives 
The secondary objectives of this study are: 
•
Part A:
o
To characterize the PK of VIR-2218 in healthy adult subjects.
•
Part B/C:
o
To characterize the PK of VIR-2218 in non-cirrhotic subjects with chronic HBV
infection on NRTI therapy.
o
To assess the antiviral activity of VIR-2218 in non-cirrhotic subjects with chronic
HBV infection on NRTI therapy.
2.3 
Endpoints 
2.3.1 Primary endpoints 
•
Part A/B/C:
o
Incidence of AEs
o
Clinical assessments including but not limited to laboratory test results
2.3.2 Secondary endpoints 
•
Part A:
o
PK parameters of VIR-2218 and possible metabolites (may include, but not
limited to plasma: maximum concentration, time to reach maximum
concentration, area under the concentration versus time curve [to last
measurable timepoint and to infinity], percent of area extrapolated, apparent
terminal elimination half-life, clearance, and volume of distribution; urine:
fraction eliminated in the urine and renal clearance).
CCI
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 12 of 41 
•
Part B/C:
o
PK parameters of VIR-2218 and possible metabolites (may include, but not
limited to plasma: maximum concentration, time to reach maximum
concentration, area under the concentration versus time curve [to the last
measurable timepoint and to infinity], apparent terminal elimination half-life,
clearance, and volume of distribution).
o
Maximum reduction of serum HBsAg from Day 1 until Week 16.
o
Number of subjects with serum HBsAg loss up to all timepoints.
o
Number of subjects with sustained serum HBsAg loss for ≥ 6 months.
o
Number of subjects with anti-HBs seroconversion at any timepoint.
o
For HBeAg-positive subjects (Part C only): number of subjects with HBeAg
loss and/or anti-HBe seroconversion at any timepoint.
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 13 of 41 
2.4 
Sample Size 
No formal sample size calculation was conducted. Up to 104 subjects (up to 56 healthy subjects 
and up to 48 subjects with chronic HBV infection) are planned to complete the study. The 209 
subjects includes “floater” subjects (up to 8 healthy subjects in Part A and up to 16 subjects 
with chronic HBV infection in Part B and C) that may be added as part of expansion of an 
existing cohort or cohorts based on SRC recommendations if further data are necessary. 
2.5 
Randomization 
An Interactive Web Response System (IWRS) will be employed to manage subject 
randomization and treatment assignments. 
Four dose-level cohorts are planned for Part A: 50 mg, 100 mg, 200 mg, and 400 mg. Two 
sentinel subjects will be randomized 1:1 to VIR-2218 or placebo. These subjects will be dosed 
concurrently and monitored for 24 hours; if the investigator has no safety concerns, the 
remainder of the subjects in the same cohort will be dosed. The remaining subjects will be 
randomized 5:1 to VIR-2218 or placebo. 
Two optional cohorts in Part A may be added following the same stratification, including sentinel 
dosing, up to a maximum dose of 900 mg. In addition to the optional cohorts, a total of 8 
“floater” subjects may be added to expand any cohort in Part A. “Floater” subjects are to be 
added in increments of 4 and randomized 3:1 to VIR-2218 or placebo. 
Three dose-level cohorts are planned for Part B: 50 mg, 100 mg, and 200 mg. One dose-level 
cohort is planned for Part C: 200 mg. Each cohort in Part B/C will be randomized 3:1 to VIR- 
2218 or placebo. 
Two optional cohorts in Part B and 2 optional cohorts in Part C may be added following the 
same stratification, up to a maximum dose of 450 mg per dose (900 mg cumulative dose). In 
addition to the optional cohorts, a pool of 16 “floater” subjects may be added to expand any 
cohort in Part B and/or C if further data are needed. “Floater” subjects are to be added in 
increments of 4 (3:1) to maintain the randomization ratio. 
In Parts A-C, blinding of study treatment will be managed by the clinical investigative site’s 
pharmacy in accordance with the Pharmacy Manual. In the event of a medical emergency 
where breaking the blind is required to provide medical care to the subject, the investigator may 
obtain treatment assignment for that subject. IWRS should be used as the primary method of 
breaking the blind. If IWRS cannot be accessed, the investigator should contact the Sponsor 
medical monitor to break the blind. Treatment assignment should remain blinded unless that 
knowledge is necessary to guide subject emergency medical care. The investigator is 
requested to contact the Sponsor medical monitor promptly in case of any treatment unblinding. 
CCI
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 14 of 41 
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to 
do so is specifically withdrawn by the subject. 
The Sponsor or designee may independently unblind cases for expedited reporting of 
suspected unexpected serious adverse reactions (SUSARs) as required by regulators. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 15 of 41 
3.
STATISTICAL CONSIDERATIONS
Data will be handled and processed per the sponsor’s representative 
 Standard 
Operating Procedures (SOPs), which are written based on the principles o  good clinical 
practice (GCP). 
3.1 
General Considerations 
All data collected on the electronic case report form (eCRF) will be presented in the data listings 
and will be listed and sorted by treatment arm, subject number and visit, where applicable. All 
summaries will be presented by treatment arm. 
When reporting descriptive statistics, the following rules will apply, except for PK concentration 
data: 
•
Continuous variables: Descriptive statistics will include the number of non-missing values
(n), arithmetic mean, standard deviation (SD), median, first quartile (Q1), third quartile
(Q3), minimum and maximum values.
The minimum and maximum values will be displayed to the same decimal precision as
the source data, the arithmetic mean, SD, median, Q1 and Q3 values will be displayed
to one more decimal than the source data for the specific variable.
The appropriate precision for derived variables will be determined based on the precision
of the data on which the derivations are based, and statistics will be presented in
accordance with the abovementioned rules.
n will be an integer. If no subjects have data at a given time point, then only n=0 will be
presented.
All data will be presented to a maximum of 3 decimal places.
•
Categorical variables: Descriptive statistics will include counts and percentages per
category. The denominator in all percentage calculations will be the number of subjects
in the relevant analysis set with non-missing data, unless specifically stated otherwise.
Percentages will be displayed to one decimal place.
Percentage change from Baseline values will be calculated and displayed to 1 decimal
place in the listings. In the summaries, the mean, SD and median percentage change
from Baseline values will be presented to 2 decimal places and the minimum and
maximum values presented to 1 decimal place.
For categories where all subjects fulfill certain criteria, the percentage value will be
displayed as 100. For categories where zero subjects fulfill certain criteria, there will be
no percentage displayed. All other percentage displays will use 1 decimal place. Data
listings will contain all reported and derived data.
Unless otherwise stated, the following methods will be applied: 
•
Repeat/unscheduled assessments: Only values collected at scheduled study visits/time
points will be presented in summary tables. If a repeat assessment was performed, the
result from the original assessment will be presented as the result at the specific visit/time
point. All collected data will be included in the data listings. Unscheduled assessments
intended as a re-test to replace missing values for scheduled visit will be used as if the
results were taken on the scheduled visit for the purpose of summary table reporting.
•
Assessment windows: All assessments will be included in the data listings and no visit
windows will be applied to exclude assessments that were performed outside of the
protocol specified procedure windows.
•
Result display convention: Results will be center aligned in all summary tables and
listings. Subject identifiers visit and parameter labels may be left-aligned if required.
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 16 of 41 
•
Date and time display conventions: The following display conventions will be applied in
all outputs where dates and/or times are displayed:

Date only: YYYY-MM-DD

Date and time: YYYY-MM-DD HH:MM
If only partial information is available, unknown components of the date or time will be 
presented as ‘NK’ (not known), i.e., ‘2016-NK-NK’. Times will be reported in military time. 
3.2 
Key Definitions 
The following definitions will be used: 
•
Baseline: The baseline value is defined as the last available valid (quantifiable continuous
or categorical value), non-missing observation for each subject prior to first study drug
administration. Repeat and unscheduled assessments will be included in the derivation of
the baseline values. Multiple pre-dose observations taken on the same date will be
averaged as baseline values.
•
Change from Baseline: The change from baseline value is defined as the difference
between the result collected/derived at a post-baseline visit/time point and the baseline
value.
The change from baseline value at each post-baseline visit/time point will be calculated
for all continuous parameters using the following formula:
Change from Baseline Value = Result at Visit/Time Point – Baseline Value 
The change from baseline value will only be calculated if the specific post-baseline 
visit/time point result and the baseline value for the parameter are both available and 
will be treated as missing otherwise. 
•
Study day: The study day of an event is defined as the relative day of the event starting
with the date of the first study drug administration (reference date) as Day 1 (there will be
no Day 0).
The study day of events occurring before the first study drug administration will be
calculated as:
Study Day = (Date of Event - Date of First Study Drug Administration) 
For events occurring on or after Day 1, study day will be calculated as: 
Study Day = (Date of Event - Date of First Study Drug Administration) + 1 
Study days will only be calculated for events with complete dates and will be undefined 
for events that are ‘Ongoing’ at the end of the study. 
Relative days compared to an alternative reference point will be calculated similarly, but 
the alternative starting reference start date will be used instead of the date of the first 
study drug dosing. 
•
HBsAg loss: quantitative HBsAg < 0.05 IU/mL at two or more consecutive
measurements
•
HBsAg Seroconversion: anti-HBs positivity at two or more consecutive measurements
•
HBeAg loss (HBeAg+ subjects only): quantitative HBeAg < 0.11 IU/mL at two or more
consecutive measurements 
•
HBeAg Seroconversion (HBeAg+ subjects only): anti-HBe positivity at two or more
consecutive measurements 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 17 of 41 
3.3 
Hypothesis Testing and Inferential Analyses 
Descriptive statistics will be used to summarize all data. No formal hypothesis testing is 
planned. 
3.4 
Multiple Comparisons and Multiplicity Adjustments. 
Not applicable for this study. 
3.5 
Coding of Events and Medications 
Adverse event verbatim terms will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) Version 21.1 or the latest version in use. Terms will be coded to the full 
MedDRA hierarchy, but the system organ class (SOC) and preferred terms (PT) will be of 
primary interest for the analysis. 
Prior and concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO-DD, March 2019 Enhanced) or the latest version in use. Medications will be 
mapped to the full WHO-DD Anatomical Therapeutic Chemical (ATC) class hierarchy, but PTs 
will be of primary interest in this analysis. 
3.6 
Cohorts (Treatment Groups) 
Part A (SAD): 
•
VIR-2218 50 mg
•
VIR-2218 100 mg
•
VIR-2218 200 mg
•
VIR-2218 400 mg
•
VIR-2218 600 mg
•
VIR-2218 900 mg
•
VIR-2218 Overall
•
Placebo
•
Overall
Part B (MAD – HBeAg-):
•
VIR-2218 20 mg
•
VIR-2218 50 mg
•
VIR-2218 100 mg
•
VIR-2218 200 mg
•
VIR-2218 Overall
•
Placebo
•
Overall
Part C (MAD – HBeAg+):
•
VIR-2218 50 mg
•
VIR-2218 200 mg
•
VIR-2218 Overall
•
Placebo
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 18 of 41 
•
Overall
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 19 of 41 
4.
ANALYSIS SETS
In this study 6 analysis sets are defined: The screened, all randomized, full analysis, safety, PK 
and antiviral analysis sets. 
Furthermore, any additional exploratory analysis not identified in the SAP will be identified in 
the final CSR as exploratory post hoc analyses, including analyses for additional study 
populations or subgroups of interest. 
The number and percentage of subjects in each analysis set will be summarized by cohort and 
overall by study part. 
4.1 
Analysis Set Descriptions 
4.1.1 Screened Analysis Set 
The screened analysis set will consist of all subjects that sign the informed consent form. The 
listing of Eligibility Criteria will be based on this population. 
4.1.2 All Randomized Analysis Set 
All subjects randomized will be included in the All Randomized Analysis Set. The All 
Randomized Analysis Set will be based on randomized treatment. Disposition data will be 
summarized by the All Randomized Analysis Set. All data, with the exception of inclusion and 
exclusion criteria, will be listed by the All Randomized Analysis Set. 
4.1.3 Full Analysis Set 
The Full Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218. 
Demographics data will be further summarized by this population set. 
4.1.4 Safety Analysis Set 
The primary analysis set for safety analyses will be the Safety Analysis Set, which includes all 
randomized subjects who received at least 1 dose of study drug. The Safety Analysis Set will 
be based on actual treatment received if different from randomized treatment. 
All safety analyses will be based on the safety analysis set. 
4.1.5 PK Analysis Set 
The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 
and 1 post-baseline PK parameter. 
4.1.6 Antiviral Activity Set 
The primary analysis set for antiviral activity analyses will be the antiviral analysis set, which 
includes all subjects in the safety analysis set who have at least 1 non-missing data to provide 
interpretable results for the specific antiviral activity parameters of interest. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 20 of 41 
5.
SUBJECT DISPOSITION AND ANALYSIS SETS
Outcomes will be summarized by treatment and overall, by study part. All outcomes will be 
listed by study part and cohort. 
5.1.1 Subject Disposition 
Subject disposition will be summarized using counts and percentages and will be based on the 
All Randomized Analysis Set for Part A to C. The number and percentage of subjects who 
completed treatment, completed the study per protocol (this means 16 week or 48 week follow 
up for the relevant parts), along with primary reason for treatment discontinuation and early 
termination will be summarized by treatment arm. 
All disposition information collected will be listed together with the date that the subject provided 
informed consent and the date and time of study drug administration. 
5.1.2 Analysis Sets 
The number of subjects included in each of the defined analysis sets will be summarized 
using counts and percentages and will be based on the all randomized set. 
In addition, the inclusion of each subject into/from each of the defined analysis sets will be 
listed by the all screened analysis set. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 21 of 41 
6.
PROTOCOL DEVIATIONS
Important Protocol deviations will be presented for each subject in the by-subject data listings 
by study part, cohort. 
Important protocol deviations may include the following, depending on the timing and nature 
of the deviation: 
•
Compromises the safety of the subject.
•
Creates a potentially unsafe condition for other subjects on the cohort or study.
•
Compromises the validity of primary results and secondary endpoints for a cohort or the
study.
•
Impairs conduct of the study.
•
Violates regulatory constraints or guidance.
•
Compromises the privacy of a subject.
Summary of major/minor protocol deviations by types will be summarized by treatment 
groups using descriptive statistics. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 22 of 41 
7.
DEMOGRAPHIC AND BASELINE INFORMATION
Demographic and baseline information will be analyzed using the Full Analysis Set. All 
summarized information will be presented by treatment and overall, by study part. All 
demographic information will be listed by cohort and study part. 
7.1 
Demographics 
7.1.1 Definition of variables 
•
Age (years)
•
Age, categorized as <30, >=30 and <40, >=40 and <50, >=50
•
Sex
•
Race
•
Ethnicity
•
BMI (kg/m2)
•
Weight (kg)
•
Country of Enrollment
•
Estimated Creatine Clearance at Screening (mL/min) by serum-creatinine based
Cockroft-Gault (C-G) equation:
For part B/C 
• 
o
Baseline HBsAg level (continuous)
o
Baseline HBsAg level, categorized as <10000 IU/mL, >=10000 IU/mL
o
Baseline ALT level (continuous)
o
Baseline ALT level, categorized as <=ULN, >ULN and <=2xULN
o
Cirrhosis status (Fibroscan results and Cirrhosis status)
7.1.2 Biostatistical methods 
Continuous and categorical summaries will be presented for demographic variables as 
discussed in section 3.1 by cohort and overall, by study part. 
7.2 
Viral Serology 
Viral serology results (Part A: Active infection with HIV infection, HCV infection, and HBV 
infection. Part B/C: Active infection with HIV infection, HCV infection, chronic HBV infection and 
hepatitis Delta virus infection. Chronic HBV infection is defined as serum HBsAg for > 6 months. 
In cases of occult HBV, chronic HBV infection is defined as serum HBV DNA positive for > 6 
months.) at screening will be listed. 
7.3 
Medical History 
Medical history will be coded using MedDRA® and will be listed. 
7.4 
Urine Drug Test 
Urine drug test results obtained at screening will be listed. 
7.5 
Cirrhosis Status 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 23 of 41 
Cirrhosis status (Fibroscan results and Cirrhosis status) at screening will be listed. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 24 of 41 
8.
TREATMENT EXPOSURE
Treatment exposure information will be described using the All Randomized Analysis Set. All 
exposure information will be listed by cohort and study part. Counts and percentages of patients 
who received full planned doses will be tabulated by cohort and study part. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 25 of 41 
9.
PHARMACOKINETICS (PK)
All PK analyses will be conducted on the plasma and urine concentration data of VIR-2218 and 
its metabolite in the PK analysis set. VIR-2218 and metabolite plasma,urine concentrations and 
PK parameter data will be listed and used for the descriptive statistics. 
Immunogenicity analysis is not in the scope of this SAP. 
9.1 DATA HANDLING FOR PK DATA 
Plasma and urine concentration values not collected or not determined will be treated as 
missing. Concentrations below the limit of quantifiable (BLQ) values will be treated as 0 prior 
to the first quantifiable concentration. BLQ values at all other timepoints will be treated as 
missing. 
9.2 SUMMARY STATISTICS FOR PK DATA 
9.2.1 Summary statistics for plasma and urine concentration data 
The units of concentration with amount or concentration in the unit, will be presented as they 
are received from the analytical laboratories. 
The actual sampling date and time and elapsed time relative to dosing time for plasma and 
urine data will be listed by subject and nominal sampling time, with time deviation (difference 
in minutes between nominal and actual sampling times) calculated, for all subjects with 
available concentration data, including subjects excluded from the PK analysis set. 
Summary statistics of PK concentration data of VIR-2218 and its metabolites (n, arithmetic 
mean, standard deviation [SD], coefficient of variation [CV%], geometric mean, geometric 
CV%, median, minimum and maximum) will be calculated for each time point and summarised 
by treatment group for healthy subjects (part A) and CHB subjects (part B and C), respectively. 
Geometric CV% calculated as the square root of the exponentiated SD of the natural log 
transformed data (SQRT(exp(sln2)-1), where appropriate. 
When reporting individual values and descriptive statistics for VIR-2218 and metabolite plasma 
and urine and concentration data, the following rules will apply regarding rounding and 
precision: 
•
Descriptive statistics for PK concentration data will be reported to the same level of
precision as the individual data for the minimum and maximum, and to 1 additional
decimal place or 1 additional significant figure – depending on the reporting format of
the original data with a maximum of 3 significant figures - for the mean (arithmetic and
geometric), median and standard deviation.
•
Between-subject CV% and geometric CV% will be reported as a percentage to 1
decimal place.
•
Subjects with dosing deviations will be listed but excluded from the summary tables.
9.2.2 Summary statistics for plasma and urine PK parameters 
Calculated PK parameters will be listed and summarized descriptively, including n, arithmetic 
mean, SD, minimum, median, maximum, coefficient of variation [CV(%)], geometric mean 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 26 of 41 
(GM), geometric SD, geometric CV%; For tmax, only n, minimum, median, and maximum will 
be reported. 
When reporting individual values and descriptive statistics for PK plasma and urine for VIR- 
2218 and its metabolites, the following rules will apply to rounding and precision: 
•
Individual values for PK parameters will be reported to 3 significant figures.
•
Descriptive statistics for PK parameters will be reported to 3 significant figures.
•
Between-subject CV% and geometric CV% will be reported as a percentage to 1
decimal place.
•
Data listings containing all documented data and all derived data will be generated.
•
Missing data will not be imputed.
•
Subjects with dosing deviations will be reported in the listings but excluded from the
summary tables.
9.1 9.3 CONCENTRATION-TIME PROFILES 
Individual (for each subject) and mean plasma VIR-2218 and metabolite concentrations will be 
displayed graphically in linear and semi-logarithmic plots of concentration versus time (hour)by 
treatment group separately for healthy subjects (part A) and CHB subjects (part B and C). The 
actual collection time will be used for plots of individual plasma concentrations and nominal 
time will be used for plots of mean plasma concentrations. Below the plots, the number of 
quantifiable concentrations per timepoint will be displayed. 
Individual (for each subject) and mean urine VIR-2218 and metabolite concentrations will be 
displayed graphically in linear and semi-logarithmic plots of concentration versus time (hour), 
by treatment group separately for healthy subjects in part A and CHB subjects (part B and C). 
The actual collection time will be used for plots of individual plasma concentrations and nominal 
time will be used for plots of mean plasma concentrations. Below the plots, the number of 
quantifiable concentrations per timepoint will be displayed. 
Subjects with dosing deviations will be excluded from the mean plots. They will be displayed in 
the individual plots with footnote. 
9.2 
Plasma PK Parameters 
Pharmacokinetic analysis will be performed on the plasma PK concentration data to determine 
PK parameters by non-compartmental analysis using Phoenix WinNonlin® software (version 
8.1 or higher). 
Actual sampling times will be used for the PK analysis and if the actual sampling time is not 
recorded, the nominal sampling time will be used. 
PK parameters (applicable for single dose cohorts in part A, day 1-dose and day-29 dose of 
multiple dose cohorts in part B and C): 
Due to the short plasma half-life of VIR-2218 and metabolite, pharmacokinetic analysis will be 
performed separately for day-1 dose and day-29 dose in patients in parts B/C. 
The following PK parameters of VIR-2218 and its metabolites to be determined at defined 
timepoints include: 
•
Cmax: Individual maximum concentration (Cmax) values are directly determined from the
plasma concentration time profiles for each subject.
•
tmax: The time to attain Cmax. If the same Cmax concentration occurs at different time
points, tmax is assigned to the first occurrence of Cmax.
•
tlast: Time of last measurable (positive) observed concentration
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 27 of 41 
•
Clast: Observed concentration corresponding to tlast.
•
AUC0-t: The areas under the curve spanning time interval from 0 to t (up to the last
time point with measurable concentration. AUC0-t will be calculated using the linear-up
/logarithmic-down trapezoidal rule.
Linear trapezoidal rule:
The area of the trapezoid between the two data points (t1, C1) and (t2, C2) where
C2≥C1 will be computed by:
Logarithmic trapezoidal rule: 
The area of the trapezoid between the two data points (t1, C1) and (t2, C2) where 
C2<C1 will be computed by: 
•
AUC0-12hr: The area under the plasma concentration-time curve over the time interval
from 0 to 12 hr using the linear-up /logarithmic-down trapezoidal rule.
•
AUC0-24hr: The area under the plasma concentration-time curve over the time interval
from 0 to 24 hr using the linear-up /logarithmic-down trapezoidal rule.
•
AUC0-∞: The area under the plasma concentration-time curve over the time interval
from 0 extrapolated to infinity will be calculated according to the following equation:
C '
AUC0−∞ = AUC0−t +   t
λ 
z 
where C't is the predicted concentration at the time t (last time point with a measurable 
plasma concentration above the quantification limit) at which quantification was still 
possible, the calculation of λz is given below. 
•
AUC%extrap: The percentage of the AUC that has been extrapolated beyond the last
observed data point, calculated as:
•
λz: The apparent terminal rate constant λz will be estimated from a regression of ln(C)
versus time over the terminal log-linear drug disposition portion of the concentration- 
time profiles. To calculate the elimination rate constant, the terminal data from a
concentration-time curve will be used. Starting with the final non-BLQ data point and
moving backwards, toward time zero, at least 3 data points not included Cmax are fit to
a linear regression. The number of data points used can be determined by maximizing
the value adjusted-r2 which defines the “best-fit” of the data.
The first order rate constant associated with the terminal (log-linear) portion of the curve
will be estimated via linear regression of time vs. log concentration. The rules are that
a minimum of three points is needed to define the terminal (log-linear) portion of the
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 28 of 41 
curve, λz must be positive, and the selection is based on the best adjusted 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 29 of 41 
square coefficient of regression (r2). Additionally, if the adjusted r2 does not improve, 
but is within 0.0001 of the largest adjusted R2 value, the regression with the larger 
number of points is used. 
The “adjusted” r2 is calculated using the following equation: 
• 
, 
where n = the number of data points used in the regression. 
The slope of the line is equal to -λz (i.e., the slope will be negative, but λz is a positive 
value). 
If terminal concentration-time point(s) increases, this time point may be included if the 
t1/2 estimate is reasonable. If λz is not determinable (for example, adjusted-r2 value 
<0.8) then consequently only parameters not requiring λz will be reported. In addition, 
the lower (Rstart) and upper (Rend) limit on time (h) for values to be included in the 
calculation of λz will be listed. 
•
t1/2: The terminal half-life will be calculated from the terminal rate constant using the
equation:
T1/ 2 = Ln(2)
λ 
z 
. 
•
CL/F: The total clearance will be calculated as following:
where D is dose. 
•
Vz/F: The apparent volume of distribution based on terminal phase will be calculated
according to the following equation:
Other important PK considerations 
•
The value of AUC%extrap will be less than or equal to 20% for the AUC0-∞ to be considered
well estimated. If this proportion is > 20%, then the values of AUC0-∞ will be treated
with caution, and emphasis will be placed on AUC0-t values (i.e. in subsequent statistical
analyses).
•
If AUC%extrap >20%, all elimination related parameters (λz, AUC0-∞, t1/2, CL/F or CL/F,ss,
and Vz/F or Vz/F,ss) will be presented in the listings but excluded from the calculation of
summary statistics. All values excluded from the summaries should be flagged in the
individual listings with an explanation for the exclusion.
•
If data permits, the other PK parameters may be reported.
•
If tlast = tmax; Cmax will not be reported for that subject in the listings. It will be footnoted
to indicate that sampling timepoints were not appropriate for that subject.
•
If tlast<24hr, AUC0-24hr will only be reported when AUC%extrap <20%; It will be presented
in the listing with footnote to indicate that AUC0-24hr was extrapolated. In the summary
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 30 of 41 
tables, the cohort will be footnoted to indicate that subjects with extrapolated AUC0-24hr
were included in the calculation of summary statistics. 
•
If tlast<12hr, AUC0-12hr will only be reported when AUC%extrap <20%; It will be presented
in the listing with footnote to indicate that AUC0-12hr was extrapolated. In the summary
tables, the cohort will be footnoted to indicate that subjects with extrapolated AUC0-12hr
were included in the calculation of summary statistics.
9.5 Urine PK Parameters 
The following urine PK parameters of VIR-2218 and its metabolites will be determined for all 
single dose and multiple dose cohorts/parts: 
•
Aet1-t2: Total amount of drug excreted in urine from time t1 to t2 hours (cumulative and
for each specific urine time intervals)
•
CLr: Renal clearance of drug (cumulative) calculated as:
•
fe- Fraction of the administered drug excreted into the urine (cumulative and for each
specific urine time intervals)
9.6 DOSE PROPORTIONALITY FOR PK PARAMETERS 
Dose proportionality will be evaluated separately for healthy subjects (part A) and day-1 dose 
of CHB subjects (part B and C) based on subjects without dosing deviations. 
To assess dose proportionality, the natural log transformed, dose normalized AUC0-∞, AUC0-t, 
AUC0-12, AUC0-24 and Cmax parameters will be evaluated using power model [2], with VIR-2218 
dose level as the independent variable. 
The power model for assessment of dose proportionality has the form of 
log(y)=log(β0)+β1log(Dose) where y represents the PK parameter of interest. Dose 
proportionality is concluded if 90% CI for the β1 falls within 0.7 to 1.43, which is less than 30% 
difference between doses for a given PK parameter. 
10.
PHARMACODYNAMICS (PD)
No PD analysis is planned for this study.
Pharmacokinetic/Pharmacodynamic analysis falls outside the scope of the SAP.
11.
EFFICACY
No efficacy analysis is planned for this study.
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 31 of 41 
12.
SAFETY
Safety endpoints will be analyzed using the safety analysis set. All information will be presented 
by cohort and overall, by study part. All safety data will be listed by cohort and study part. 
12.1 Adverse Events 
12.1.1 Definition of variables 
•
AE
•
Serious adverse event (SAE)
•
Treatment emergent adverse event (TEAE)
AEs and SAEs are defined in the study protocol. TEAEs are defined as any AEs with an onset 
date of on or after the study drug start date and no later than 30 days after permanent 
discontinuation of study drug. Adverse events that have missing onset dates will be considered 
treatment-emergent, unless the stop date is known to be prior to the first administration of the 
study medication. 
12.1.2 Biostatistical methods 
All AEs including will be coded using MedDRA. 
All AE summaries will be restricted to TEAEs only. Summary tables will include the number of 
subjects (%) experiencing an event and the number of events. Subjects will be counted only 
once at each SOC and PT level of summary. 
The TEAE summaries will include: 
•
Overall Summary of TEAEs
•
TEAE summary by SOC and PT
•
TEAE summary of serious events by SOC and PT
•
TEAE summary by causality to study drug by SOC and PT
•
TEAE summary by maximum toxicity
•
TEAE summary by SOC, PT and maximum toxicity
All SOC by PT tables will be sorted by PT in descending order of total occurrence for each part. 
All AEs will be listed and will include verbatim term, PT, SOC, treatment, severity, relationship, 
seriousness, outcome, and action taken with regards to the study drug. Separate listings will be 
created for AEs leading to study withdrawal and SAEs. 
12.2 Safety Laboratory Assessments 
Blood and urine samples will be collected at the time points specified in the schedule of events 
(refer to the Protocol) to conduct hematology, coagulation, chemistry and urinalysis analyses. 
The following tests will be performed within each of the specified test panels: 
Hematology: 
•
Complete blood count with differential
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 32 of 41 
Chemistry: 
•
Albumin
•
Creatinine clearance
•
Blood urea nitrogen (BUN)
•
Gamma glutamyl transferase (GGT)
•
Calcium
•
Glucose
•
Carbon dioxide/bicarbonate
•
Lactate dehydrogenase (LDH)
•
Chloride
•
Potassium
•
Creatine kinase
•
Sodium
•
Creatinine
•
Urea
•
Uric acid
•
Liver Function Tests
o
Alkaline phosphatase (ALP)
o
AST
o
ALT
o
Bilirubin (total and direct)
Coagulation: 
•
International normalized ratio (INR) time
•
Prothrombin
Urinalysis & Microscopic Urinalysis:
•
Specific gravity
•
pH
•
Glucose
•
Proteins
•
Red Blood Cells
•
Ketones
•
Bilirubin
•
Urobilinogen
•
Nitrite
•
Leukocytes
•
Visual inspection for appearance and color
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 33 of 41 
•
Microscopy (if clinically indicated)
12.2.1 Biostatistical Methods 
All laboratory data collected at scheduled and unscheduled visits will be included in the listings, 
but only results collected as scheduled visits will be included in the summary tables. 
Results for individual parameters may be reported in different units depending on the analyzing 
laboratory. If required, the results (and the corresponding normal range cut-off values) for 
individual parameters may be converted to International System of Units (S.I.) units to 
summarize the data. 
For all the parameters where a unit value has been reported, the parameter names that will 
be used in the outputs will comprise of the test name and the unit of measure, for example, 
‘Albumin (g/L)’. Parameters will be sorted alphabetically within tables and listings. 
For all parameters where a normal range limit value is reported, the normal range will be derived 
based on the available lower and upper limit values and any reported mathematical symbols. 
If both a lower and upper limit value is available, the normal range will be presented as ‘(Lower, 
Upper)’. 
The reported results for each parameter with a defined normal range will be classified (‘Low’, 
‘or ‘High’) in relation to the defined normal range limits. If a result is equal to the normal range 
cut-off value, the result will be considered normal. 
The change from baseline values at each post-baseline visit will be calculated for all 
parameters with continuous results. 
The decimal precision to which the summaries for each parameter will be based on the 
maximum number of decimals to which the reported result or the normal range limits are 
presented to in the raw data. The results and normal ranges will be displayed to the same 
decimal precision in the listings. 
The hematology and chemistry results tables will present summary statistics for each laboratory 
parameter within the specific test panel. For each parameter, summaries will be presented for 
the baseline and each scheduled post-baseline visit. In addition, summaries will be presented 
for the change from baseline values at each scheduled post-baseline visit. 
Additionally, shift tables from baseline in CTCAE grade (version 5) from baseline will be 
summarized by counts and percentages along with a summary of maximum CTCAE Grade for 
post treatment lab assessments The summary for the maximum CTCAE will be based on both 
scheduled and unscheduled visits. 
The urinalysis table will present counts and percentages for the reported results at baseline 
and each post-baseline visit within each test parameter. Result categories will be order 
alphabetically, or in ascending order. 
The listings of laboratory parameters will include all the information (fields) collected (including 
CTCAE derived values). In addition, the observations that are used as the baseline record 
(value) for each parameter will be flagged, and the change from baseline values at each post-
baseline visit will be presented. 
12.3 Vital Signs Measurements 
The following vital signs measurements will be taken at the time points specified in the 
Schedule of Events (refer to the Protocol): 
•
Pulse Rate (beats/min)
•
Systolic blood pressure (SBP) (mmHg)
•
Diastolic blood pressure (DBP) (mmHg)
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 34 of 41 
•
Respiratory rate (breaths/min)
•
Temperature (ºC)
12.3.1 Biostatistical Methods 
All vital signs data collected at scheduled and unscheduled visits will be included in the listings, 
but only results collected as scheduled visits will be included in the summary tables. 
The parameter names that will be used in the outputs will comprise of the test name and the 
unit of measure, for example, ‘Systolic Blood Pressure (mmHg)’. Parameters will be sorted in 
the order that the measurements were collected in on the Vital Signs eCRF page within the 
tables and listings. 
The change from baseline to the pre-dose assessment at each post-baseline visit will be 
calculated for all parameters. If unscheduled assessments are recorded on Day 1, the average 
of the pre-dose Day 1 and unscheduled assessments will be used as baseline for all change 
from baseline calculations. 
The decimal precision to which the summaries for each parameter will presented will be 
based on the maximum number of decimals to which the results were reported on the eCRF. 
Vital signs measurements will present summary statistics for the results at the baseline and 
each scheduled post-baseline visit for each of the parameters. In addition, summaries will be 
presented for the change from baseline values at each scheduled post-baseline visit. 
The listings of vital signs measurements will include all the information collected. In addition, 
the observations that are used as the baseline record (value) for each parameter will be 
flagged, and the change from baseline values at each post-baseline visit will be presented. 
12.4 12-Lead Safety Electrocardiogram (ECG) 
12-lead safety ECGs interpretations will be recorded and reviewed on-site by the investigator
as outlined in the protocol scheduled of event in Appendix 2 and Appendix 3. Specified
collection timepoints for each visit are provided in the protocol: Appendix 4 and Appendix 5.
Holter ECG analysis falls outside the scope of the study. 
12.4.1 Biostatistical Methods 
All ECG data collected at scheduled and unscheduled visits will be included in the listings, but 
only results collected as scheduled visits will be included in the summary tables. 
The summary of overall interpretation findings table will present counts and percentages for 
the reported results at baseline and each post-baseline visit/time point. Result categories will 
be ordered as ‘Normal’, ‘Abnormal Not Clinically Significant (NCS)’ and ‘Abnormal Clinically 
Significant (CS)’. 
The listings of ECG measurements will include all the information collected data. In addition, 
the observations that are used as the baseline record (value) for each parameter will be 
flagged, and the change from baseline values at each post-baseline visit will be presented. 
12.5 Physical Examinations 
Physical Examination assessments will be listed for all time points. 
12.6 Substance Use 
Alcohol consumption within 7 days prior to each visit will be listed. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 35 of 41 
12.7 Pregnancy Test Results 
All information related to pregnancy testing (urine and serum based - beta-human chorionic 
gonadotropin) and contraception status will be listed. This listing will include all pregnancy test 
results collected during the study. 
12.8 Concomitant Medications 
Prior medications are defined as any medication where the use was stopped prior to the first 
administration of the study medication. 
Concomitant medications are defined as any medication (other than the study drug) that was 
used at least once after the first administration of the study medication. Medications that were 
stopped on the same date as the first study drug administration will be analyzed as concomitant 
medications. If a clear determination cannot be made (partial medication end dates) the 
medication will be classified as concomitant. 
12.8.1 Biostatistical Methods 
Concomitant medications will be summarized by ATC class Level 3 and PT. Within each 
category, the number of subjects who used the medication (count and percentage) will be 
presented. Subject who used the same medication on multiple occasions will only be counted 
once in the specific category (PT). PTs will be sorted alphabetically. In addition to the 
summaries by the coded terms, the number of subjects who used at least one concomitant 
medication during the study will be presented. 
All information that was collected on the Concomitant Medication eCRF as well as the coded 
WHO-DD terms will be included in the listings. 
Prior medications will be listed only. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 36 of 41 
13.
ANTIVIRAL ACTIVITY
Antiviral activity endpoints will be analyzed using the antiviral analysis set. All information will 
be presented by treatment group, overall by study part (Parts B & C). All antiviral activity data 
will be listed by cohort and study part. 
13.1 Definition of variables 
•
Maximum reduction of serum HBsAg from Day 1 until Week 16.
o
Serum log10 HBsAg levels by timepoint
o
Serum log10 HBsAg levels < 10000 IU/mL, <1000 IU/mL and < 100 IU/mL by
timepoint
•
Serum log10 HBsAg Nadir level per subject, summarize as continuous and categories
of < 10000 IU/mL, <1000 IU/mL and < 100 IU/mL
•
Time to Nadir, Nadir value and Nadir change from baseline value
•
Number of subjects with serum HBsAg loss at any timepoint.
•
Number of subjects with sustained serum HBsAg loss for ≥ 6 months.
•
Number of subjects with anti-HBs seroconversion at any timepoint.
•
For HBeAg-positive subjects (Part C only): number of subjects with HBeAg loss and/or
anti-HBe seroconversion at any timepoint.
13.2 Biostatistical methods 
All antiviral data collected at scheduled and unscheduled visits will be included in the listings, 
but only results collected as scheduled visits will be included in the summary tables. 
The parameter names that will be used in the outputs will comprise of the test name and the 
unit of measure, for example, HBsAg (IU/mL). For HBV DNA both IU/mL and copies/mL 
 will be presented. For HBV DNA, undetected and <LOQ will be 
imputed as 9
U mL. Parameters will be sorted within parameter class (if present) in 
alphabetical order within the tables and listings. 
Summary for serum log10 HBsAg nadir level and time to nadir will be based on all scheduled 
and un-scheduled post-baseline visits. Measurements will present summary statistics for the 
results at the baseline and each scheduled post-baseline visit for each of the parameters. In 
addition, summaries will be presented for the change from baseline of the antiviral measure 
to that assessed at baseline values at each scheduled post-baseline visit. See section 3.1 for 
more detail with regards continuous data representation. Categorical summaries (% of 
subjects) will present counts and percentages for the reported results at baseline and each 
post-baseline time point. Additionally, HBV DNA 
will be summarized into TND, 
<LOQ, and >LOQ categories. 
CCI
CCI
CCI
CCI
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 37 of 41 
14.
HANDLING OF MISSING DATA
All data will be analyzed as collected and missing values will not be imputed nor replaced.
Laboratory data that are continuous in nature but are less than the LLOQ (or LOD) or above 
the upper limit of quantitation, will be imputed to the value of the lower or upper limit minus or 
plus 1 significant digit, respectively (e.g., if the result of a continuous laboratory test is < 30, a 
value of 29 will be assigned; if the result of a continuous laboratory test is <30.0, a value of 
29.9 will be assigned). If the results of continuous lab test is <1, the imputed value should be 
0.9; If the results of the lab test is <0.1, the imputed value should be 0.09. The actual 
reported values will be provided in by-subject listings. 
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 38 of 41 
15.
CHANGES TO THE PLANNED ANALYSIS
Not applicable.
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 39 of 41 
16.
INTERIM AND FINAL ANALYSIS
16.1 
Interim Analysis 1 
The first interim analysis for the study will be based on all data captured up to the time of the 
data freeze for the analysis. 
After data cleaning and database soft lock, the study will be unblinded by treatment group at 
a subject level. The following outputs will be included as part of the interim analysis: 
CCI
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 40 of 41 
16.2 Final Analysis (End of Study) 
The final analysis will be conducted after all subjects have completed the study, the clinical 
database has been locked and the analysis sets have been approved. 
The final analysis will be based on the final version of the SAP. Any deviations from the 
planned analysis will be documented in the CSR. 
CCI
PPD


Protocol Number: VIR-2218-1001 
Document status: Version 2.3 
2020-12-22 
Page 41 of 41 
17.
SOFTWARE
•
The following software will be used to perform the statistical analyses: SAS® Version
9.2 or higher (SAS Institute, Cary, North Carolina, USA).
PPD


Page 40 of 41 
Protocol Number: VIR-2218-1001 
2020-12-22 
Document status: Version 2.3 
18.
TABLES, LISTINGS AND FIGURES
CCI
PPD


Page 41 of 41 
Protocol Number: VIR-2218-1001 
2020-12-22 
Document status: Version 2.3 
19.
REFERENCES
1)
Clinical Study Amendment 2.0 dated 27 March 2019.
2)
Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment
of dose proportionality. Pharm Res. 2000;17(10):1278-1283.
doi:10.1023/a:1026451721686
3)
National Cancer Institute (USA) Common Terminology Criteria for Adverse Events
(CTCAE) v5.0
PPD